6	CD	6	6	6	N	O
ADVERSE	JJ	adverse	adverse	advers	N	O
REACTIONS	NN	reactions	reaction	reaction	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
frequently	RB	frequently	frequently	frequent	N	O
reported	VBD	reported	reported	report	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
5%	CD	5%	5%	5%	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
were	VBD	were	were	were	N	O
hypersensitivity	JJ	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
and	CC	and	and	and	N	O
included	VBD	included	included	includ	N	O
:	:	:	:	:	N	O
anaphylaxis	NN	anaphylaxis	anaphylaxis	anaphylaxi	Y	B-AdverseReaction
,	,	,	,	,	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction
,	,	,	,	,	N	O
pyrexia	NN	pyrexia	pyrexia	pyrexia	Y	B-AdverseReaction
,	,	,	,	,	N	O
flushing	VBG	flushing	flushing	flush	Y	B-AdverseReaction
feeling	VBG	feeling	feeling	feel	N	B-AdverseReaction
hot	JJ	hot	hot	hot	N	I-AdverseReaction
,	,	,	,	,	N	O
urticaria	JJ	urticaria	urticaria	urticaria	Y	B-AdverseReaction
,	,	,	,	,	N	O
headache	NN	headache	headache	headach	Y	B-AdverseReaction
,	,	,	,	,	N	O
hyperhidrosis	NN	hyperhidrosis	hyperhidrosis	hyperhidrosi	Y	B-AdverseReaction
,	,	,	,	,	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
,	,	,	,	,	N	O
cough	NN	cough	cough	cough	Y	B-AdverseReaction
,	,	,	,	,	N	O
decreased	VBD	decreased	decreased	decreas	N	B-AdverseReaction
oxygen	NN	oxygen	oxygen	oxygen	N	I-AdverseReaction
saturation	NN	saturation	saturation	satur	N	I-AdverseReaction
,	,	,	,	,	N	O
tachycardia	NN	tachycardia	tachycardia	tachycardia	Y	B-AdverseReaction
,	,	,	,	,	N	O
tachypnea	NN	tachypnea	tachypnea	tachypnea	Y	B-AdverseReaction
,	,	,	,	,	N	O
chest	NN	chest	chest	chest	N	B-AdverseReaction
discomfort	NN	discomfort	discomfort	discomfort	Y	I-AdverseReaction
,	,	,	,	,	N	O
dizziness	NN	dizziness	dizziness	dizzi	Y	B-AdverseReaction
,	,	,	,	,	N	O
muscle	NN	muscle	muscle	muscl	N	B-AdverseReaction
twitching	NN	twitching	twitching	twitch	Y	I-AdverseReaction
,	,	,	,	,	N	O
agitation	NN	agitation	agitation	agit	Y	B-AdverseReaction
,	,	,	,	,	N	O
cyanosis	NN	cyanosis	cyanosis	cyanosi	Y	B-AdverseReaction
,	,	,	,	,	N	O
erythema	NN	erythema	erythema	erythema	Y	B-AdverseReaction
,	,	,	,	,	N	O
hypertension	NN	hypertension	hypertension	hypertens	Y	B-AdverseReaction
increased	VBD	increased	increased	increas	N	B-AdverseReaction
blood	NN	blood	blood	blood	N	I-AdverseReaction
pressure	NN	pressure	pressure	pressur	N	I-AdverseReaction
,	,	,	,	,	N	O
pallor	NN	pallor	pallor	pallor	Y	B-AdverseReaction
,	,	,	,	,	N	O
rigors	NNS	rigors	rigor	rigor	Y	B-AdverseReaction
,	,	,	,	,	N	O
tremor	NN	tremor	tremor	tremor	Y	B-AdverseReaction
,	,	,	,	,	N	O
vomiting	VBG	vomiting	vomiting	vomit	Y	B-AdverseReaction
,	,	,	,	,	N	O
fatigue	NN	fatigue	fatigue	fatigu	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
myalgia	NN	myalgia	myalgia	myalgia	Y	B-AdverseReaction
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

To	TO	to	to	to	N	O
report	VB	report	report	report	N	O
SUSPECTED	NNP	suspected	suspected	suspect	N	O
ADVERSE	NNP	adverse	adverse	advers	N	O
REACTIONS	NNP	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
contact	NN	contact	contact	contact	N	O
Genzyme	NNP	genzyme	genzyme	genzym	N	O
at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
800	CD	800	800	800	N	O
-	:	-	-	-	N	O
745	CD	745	745	745	N	O
-	:	-	-	-	N	O
4447	CD	4447	4447	4447	N	O
or	CC	or	or	or	N	O
FDA	NNP	fda	fda	fda	N	O
at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
800	CD	800	800	800	N	O
-	:	-	-	-	N	O
FDA	NNP	fda	fda	fda	N	O
-	:	-	-	-	N	O
1088	CD	1088	1088	1088	N	O
or	CC	or	or	or	N	O
www	VB	www	www	www	N	O
.	.	.	.	.	N	O
fda	NN	fda	fda	fda	N	O
.	.	.	.	.	N	O
gov	NN	gov	gov	gov	N	O
medwatch	NN	medwatch	medwatch	medwatch	N	O

6.1	CD	6.1	6.1	6.1	N	O

Clinical	JJ	clinical	clinical	clinic	N	O

Trials	NNS	trials	trial	trial	N	O
Experience	NN	experience	experience	experi	N	O

Because	IN	because	because	becaus	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
are	VBP	are	are	are	N	O
conducted	VBN	conducted	conducted	conduct	N	O
under	IN	under	under	under	N	O
widely	RB	widely	widely	wide	N	O
varying	VBG	varying	varying	vari	N	O
conditions	NNS	conditions	condition	condit	N	O
,	,	,	,	,	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
drug	NN	drug	drug	drug	N	O
cannot	NN	cannot	cannot	cannot	N	O
be	VB	be	be	be	N	O
directly	RB	directly	directly	directli	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
rates	NNS	rates	rate	rate	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
another	DT	another	another	anoth	N	O
drug	NN	drug	drug	drug	N	O
and	CC	and	and	and	N	O
may	MD	may	may	may	N	O
not	RB	not	not	not	N	O
reflect	VB	reflect	reflect	reflect	N	O
the	DT	the	the	the	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
practice	NN	practice	practice	practic	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
following	VBG	following	following	follow	N	O
serious	JJ	serious	serious	seriou	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
are	VBP	are	are	are	N	O
described	VBN	described	described	describ	N	O
below	IN	below	below	below	N	O
and	CC	and	and	and	N	O
elsewhere	RB	elsewhere	elsewhere	elsewher	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
labeling	NN	labeling	labeling	label	N	O
:	:	:	:	:	N	O

Anaphylaxis	NNP	anaphylaxis	anaphylaxis	anaphylaxi	Y	O
and	CC	and	and	and	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	O
reactions	NNS	reactions	reaction	reaction	N	O
[	VBP	[	[	[	N	O
seeWarnings	NNS	seewarnings	seewarnings	seewarn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
5%	CD	5%	5%	5%	N	O
)	)	)	)	)	N	O
following	VBG	following	following	follow	N	O
alglucosidase	JJ	alglucosidase	alglucosidase	alglucosidas	N	O
alfa	JJ	alfa	alfa	alfa	N	O
treatment	NN	treatment	treatment	treatment	N	O
were	VBD	were	were	were	N	O
hypersensitivity	JJ	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
included	VBD	included	included	includ	N	O
anaphylaxis	NN	anaphylaxis	anaphylaxis	anaphylaxi	Y	B-AdverseReaction
,	,	,	,	,	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction
,	,	,	,	,	N	O
pyrexia	NN	pyrexia	pyrexia	pyrexia	Y	B-AdverseReaction
,	,	,	,	,	N	O
flushing	VBG	flushing	flushing	flush	Y	B-AdverseReaction
feeling	VBG	feeling	feeling	feel	N	B-AdverseReaction
hot	JJ	hot	hot	hot	N	I-AdverseReaction
,	,	,	,	,	N	O
urticaria	JJ	urticaria	urticaria	urticaria	Y	B-AdverseReaction
,	,	,	,	,	N	O
headache	NN	headache	headache	headach	Y	B-AdverseReaction
,	,	,	,	,	N	O
hyperhidrosis	NN	hyperhidrosis	hyperhidrosis	hyperhidrosi	Y	B-AdverseReaction
,	,	,	,	,	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
,	,	,	,	,	N	O
cough	NN	cough	cough	cough	Y	B-AdverseReaction
,	,	,	,	,	N	O
decreased	VBD	decreased	decreased	decreas	N	B-AdverseReaction
oxygen	NN	oxygen	oxygen	oxygen	N	I-AdverseReaction
saturation	NN	saturation	saturation	satur	N	I-AdverseReaction
,	,	,	,	,	N	O
tachycardia	NN	tachycardia	tachycardia	tachycardia	Y	B-AdverseReaction
,	,	,	,	,	N	O
tachypnea	NN	tachypnea	tachypnea	tachypnea	Y	B-AdverseReaction
,	,	,	,	,	N	O
chest	NN	chest	chest	chest	N	B-AdverseReaction
discomfort	NN	discomfort	discomfort	discomfort	Y	I-AdverseReaction
,	,	,	,	,	N	O
dizziness	NN	dizziness	dizziness	dizzi	Y	B-AdverseReaction
,	,	,	,	,	N	O
muscle	NN	muscle	muscle	muscl	N	B-AdverseReaction
twitching	NN	twitching	twitching	twitch	Y	I-AdverseReaction
,	,	,	,	,	N	O
agitation	NN	agitation	agitation	agit	Y	B-AdverseReaction
,	,	,	,	,	N	O
cyanosis	NN	cyanosis	cyanosis	cyanosi	Y	B-AdverseReaction
,	,	,	,	,	N	O
erythema	NN	erythema	erythema	erythema	Y	B-AdverseReaction
,	,	,	,	,	N	O
hypertension	NN	hypertension	hypertension	hypertens	Y	B-AdverseReaction
increased	VBD	increased	increased	increas	N	B-AdverseReaction
blood	NN	blood	blood	blood	N	I-AdverseReaction
pressure	NN	pressure	pressure	pressur	N	I-AdverseReaction
,	,	,	,	,	N	O
pallor	NN	pallor	pallor	pallor	Y	B-AdverseReaction
,	,	,	,	,	N	O
rigors	NNS	rigors	rigor	rigor	Y	B-AdverseReaction
,	,	,	,	,	N	O
tremor	NN	tremor	tremor	tremor	Y	B-AdverseReaction
,	,	,	,	,	N	O
vomiting	VBG	vomiting	vomiting	vomit	Y	B-AdverseReaction
,	,	,	,	,	N	O
fatigue	NN	fatigue	fatigue	fatigu	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
myalgia	NN	myalgia	myalgia	myalgia	Y	B-AdverseReaction
.	.	.	.	.	N	O

Clinical	JJ	clinical	clinical	clinic	N	O

Trials	NNS	trials	trial	trial	N	O
in	IN	in	in	in	N	O
Infantile	NNP	infantile	infantile	infantil	N	O
-	:	-	-	-	N	O
Onset	NN	onset	onset	onset	N	O
and	CC	and	and	and	N	O
Juvenile	NNP	juvenile	juvenile	juvenil	N	O
-	:	-	-	-	N	O
Onset	NNP	onset	onset	onset	N	O
Pompe	NNP	pompe	pompe	pomp	N	O
Disease	NNP	disease	disease	diseas	N	O

Two	CD	two	two	two	N	O
multicenter	NN	multicenter	multicenter	multicent	N	O
,	,	,	,	,	N	O
open	JJ	open	open	open	N	O
-	:	-	-	-	N	O
label	NN	label	label	label	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
were	VBD	were	were	were	N	O
conducted	VBN	conducted	conducted	conduct	N	O
in	IN	in	in	in	N	O
39	CD	39	39	39	N	O
infantile	JJ	infantile	infantile	infantil	N	O
-	:	-	-	-	N	O
onset	NN	onset	onset	onset	N	O
Pompe	NNP	pompe	pompe	pomp	N	O
disease	NN	disease	disease	diseas	N	O
patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
ages	NNS	ages	age	age	N	O
1	CD	1	1	1	N	O
month	NN	month	month	month	N	O
to	TO	to	to	to	N	O
3.5	CD	3.5	3.5	3.5	N	O
years	NNS	years	year	year	N	O
old	JJ	old	old	old	N	O
.	.	.	.	.	N	O

Approximately	RB	approximately	approximately	approxim	N	O
half	NN	half	half	half	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
54%	CD	54%	54%	54%	N	O
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
male	JJ	male	male	male	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
were	VBD	were	were	were	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
alglucosidase	NN	alglucosidase	alglucosidase	alglucosidas	N	O
alfa	NN	alfa	alfa	alfa	N	O
20	CD	20	20	20	N	O
or	CC	or	or	or	N	O
40	CD	40	40	40	N	O
mg	NNS	mg	mg	mg	N	O
kg	VBN	kg	kg	kg	N	O
every	DT	every	every	everi	N	O
other	JJ	other	other	other	N	O
week	NN	week	week	week	N	O
for	IN	for	for	for	N	O
periods	NNS	periods	period	period	N	O
ranging	VBG	ranging	ranging	rang	N	O
from	IN	from	from	from	N	O
1	CD	1	1	1	N	O
to	TO	to	to	to	N	O
106	CD	106	106	106	N	O
weeks	NNS	weeks	week	week	N	O
(	(	(	(	(	N	O
mean	NN	mean	mean	mean	N	O
:	:	:	:	:	N	O
61	CD	61	61	61	N	O
weeks	NNS	weeks	week	week	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
serious	JJ	serious	serious	seriou	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
reported	VBN	reported	reported	report	N	O
with	IN	with	with	with	N	O
alglucosidase	NN	alglucosidase	alglucosidase	alglucosidas	N	O
alfa	NN	alfa	alfa	alfa	N	O
treatment	NN	treatment	treatment	treatment	N	O
included	VBD	included	included	includ	N	O
anaphylaxis	NN	anaphylaxis	anaphylaxis	anaphylaxi	Y	B-AdverseReaction
and	CC	and	and	and	N	O
acute	JJ	acute	acute	acut	N	B-AdverseReaction
cardiorespiratory	NN	cardiorespiratory	cardiorespiratory	cardiorespiratori	N	I-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
requiring	VBG	requiring	requiring	requir	N	O
intervention	NN	intervention	intervention	intervent	N	O
in	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
were	VBD	were	were	were	N	O
hypersensitivity	JJ	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
,	,	,	,	,	N	O
occurring	VBG	occurring	occurring	occur	N	O
in	IN	in	in	in	N	O
20	CD	20	20	20	N	O
of	IN	of	of	of	N	O
39	CD	39	39	39	N	O
(	(	(	(	(	N	O
51%	CD	51%	51%	51%	N	O
)	)	)	)	)	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
alglucosidase	NN	alglucosidase	alglucosidase	alglucosidas	N	O
alfa	NN	alfa	alfa	alfa	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
included	VBD	included	included	includ	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction
,	,	,	,	,	N	O
pyrexia	NN	pyrexia	pyrexia	pyrexia	Y	B-AdverseReaction
,	,	,	,	,	N	O
urticaria	NN	urticaria	urticaria	urticaria	Y	B-AdverseReaction
,	,	,	,	,	N	O
flushing	NN	flushing	flushing	flush	Y	B-AdverseReaction
,	,	,	,	,	N	O
decreased	VBD	decreased	decreased	decreas	N	B-AdverseReaction
oxygen	NN	oxygen	oxygen	oxygen	N	I-AdverseReaction
saturation	NN	saturation	saturation	satur	N	I-AdverseReaction
,	,	,	,	,	N	O
cough	NN	cough	cough	cough	Y	B-AdverseReaction
,	,	,	,	,	N	O
tachypnea	NN	tachypnea	tachypnea	tachypnea	Y	B-AdverseReaction
,	,	,	,	,	N	O
tachycardia	NN	tachycardia	tachycardia	tachycardia	Y	B-AdverseReaction
,	,	,	,	,	N	O
hypertension	NN	hypertension	hypertension	hypertens	Y	B-AdverseReaction
increased	VBD	increased	increased	increas	N	B-AdverseReaction
blood	NN	blood	blood	blood	N	I-AdverseReaction
pressure	NN	pressure	pressure	pressur	N	I-AdverseReaction
,	,	,	,	,	N	O
pallor	NN	pallor	pallor	pallor	Y	B-AdverseReaction
,	,	,	,	,	N	O
rigors	NNS	rigors	rigor	rigor	Y	B-AdverseReaction
,	,	,	,	,	N	O
vomiting	VBG	vomiting	vomiting	vomit	Y	B-AdverseReaction
,	,	,	,	,	N	O
cyanosis	NN	cyanosis	cyanosis	cyanosi	Y	B-AdverseReaction
,	,	,	,	,	N	O
agitation	NN	agitation	agitation	agit	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
tremor	NN	tremor	tremor	tremor	Y	B-AdverseReaction
.	.	.	.	.	N	O

These	DT	these	these	these	N	O
reactions	NNS	reactions	reaction	reaction	N	O
were	VBD	were	were	were	N	O
more	RBR	more	more	more	N	O
likely	JJ	likely	likely	like	N	O
to	TO	to	to	to	N	O
occur	VB	occur	occur	occur	N	O
with	IN	with	with	with	N	O
higher	JJR	higher	higher	higher	N	O
infusion	NN	infusion	infusion	infus	Y	O
rates	NNS	rates	rate	rate	N	O
.	.	.	.	.	N	O

Some	DT	some	some	some	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
were	VBD	were	were	were	N	O
pre	JJ	pre	pre	pre	N	O
-	:	-	-	-	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
antihistamines	NNS	antihistamines	antihistamine	antihistamin	N	O
,	,	,	,	,	N	O
antipyretics	NNS	antipyretics	antipyretic	antipyret	N	O
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
corticosteroids	NNS	corticosteroids	corticosteroid	corticosteroid	N	O
still	RB	still	still	still	N	O
experienced	VBD	experienced	experienced	experienc	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
2	CD	2	2	2	N	O
summarizes	VBZ	summarizes	summarizes	summar	N	O
all	DT	all	all	all	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
occurring	VBG	occurring	occurring	occur	N	O
in	IN	in	in	in	N	O
5%	CD	5%	5%	5%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
2	CD	2	2	2	N	O
or	CC	or	or	or	N	O
more	JJR	more	more	more	N	O
patients	NNS	patients	patient	patient	N	O
)	)	)	)	)	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
alglucosidase	NN	alglucosidase	alglucosidase	alglucosidas	N	O
alfa	NN	alfa	alfa	alfa	N	O
in	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
described	VBN	described	described	describ	N	O
above	IN	above	above	abov	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
2	CD	2	2	2	N	O
:	:	:	:	:	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNS	reactions	reaction	reaction	N	O
that	WDT	that	that	that	N	O
Occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
At	IN	at	at	at	N	O
Least	NNP	least	least	least	N	O
5%	CD	5%	5%	5%	N	O
of	IN	of	of	of	N	O
Infantile	NNP	infantile	infantile	infantil	N	O
-	:	-	-	-	N	O
Onset	NN	onset	onset	onset	N	O
Patients	NNS	patients	patient	patient	N	O
Treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
Alglucosidase	NNP	alglucosidase	alglucosidase	alglucosidas	N	O
Alfa	NNP	alfa	alfa	alfa	N	O
in	IN	in	in	in	N	O
Clinical	NNP	clinical	clinical	clinic	N	O
Trials	NNS	trials	trial	trial	N	O

Number	NNP	number	number	number	N	O
of	IN	of	of	of	N	O
Patients	NNP	patients	patient	patient	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
39	CD	39	39	39	N	O
)	)	)	)	)	N	O
n	FW	n	n	n	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O

Adverse	JJ	adverse	adverse	advers	N	O
Reaction	NNP	reaction	reaction	reaction	N	O
20	CD	20	20	20	N	O
(	(	(	(	(	N	O
51	CD	51	51	51	N	O
)	)	)	)	)	N	O

Rash	NN	rash	rash	rash	Y	B-AdverseReaction

(	(	(	(	(	N	O
including	VBG	including	including	includ	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction
erythematous	JJ	erythematous	erythematous	erythemat	N	I-AdverseReaction
,	,	,	,	,	N	O
rash	JJ	rash	rash	rash	Y	B-AdverseReaction
macular	NN	macular	macular	macular	N	I-AdverseReaction
and	CC	and	and	and	N	O
maculo	SYM	maculo	maculo	maculo	N	I-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
papular	NN	papular	papular	papular	N	I-AdverseReaction
)	)	)	)	)	N	O
7	CD	7	7	7	N	O
(	(	(	(	(	N	O
18	CD	18	18	18	N	O
)	)	)	)	)	N	O

Pyrexia	$	pyrexia	pyrexia	pyrexia	Y	B-AdverseReaction
6	CD	6	6	6	N	O
(	(	(	(	(	N	O
15	CD	15	15	15	N	O
)	)	)	)	)	N	O

Urticaria	NNS	urticaria	urticaria	urticaria	Y	B-AdverseReaction
5	CD	5	5	5	N	O
(	(	(	(	(	N	O
13	CD	13	13	13	N	O
)	)	)	)	)	N	O

Flushing	VBG	flushing	flushing	flush	Y	B-AdverseReaction
5	CD	5	5	5	N	O
(	(	(	(	(	N	O
13	CD	13	13	13	N	O
)	)	)	)	)	N	O

Hypertension	NN	hypertension	hypertension	hypertens	Y	B-AdverseReaction
Increased	VBD	increased	increased	increas	N	B-AdverseReaction
Blood	NNP	blood	blood	blood	N	I-AdverseReaction
Pressure	NN	pressure	pressure	pressur	N	I-AdverseReaction
4	CD	4	4	4	N	O
(	(	(	(	(	N	O
10	CD	10	10	10	N	O
)	)	)	)	)	N	O

Decreased	VBN	decreased	decreased	decreas	N	B-AdverseReaction
Oxygen	NNP	oxygen	oxygen	oxygen	N	I-AdverseReaction
Saturation	NNP	saturation	saturation	satur	N	I-AdverseReaction
3	CD	3	3	3	N	O
(	(	(	(	(	N	O
8	CD	8	8	8	N	O
)	)	)	)	)	N	O

Cough	IN	cough	cough	cough	Y	B-AdverseReaction
3	CD	3	3	3	N	O
(	(	(	(	(	N	O
8	CD	8	8	8	N	O
)	)	)	)	)	N	O

Tachypnea	NN	tachypnea	tachypnea	tachypnea	Y	B-AdverseReaction
3	CD	3	3	3	N	O
(	(	(	(	(	N	O
8	CD	8	8	8	N	O
)	)	)	)	)	N	O

Tachycardia	NNP	tachycardia	tachycardia	tachycardia	Y	B-AdverseReaction
3	CD	3	3	3	N	O
(	(	(	(	(	N	O
8	CD	8	8	8	N	O
)	)	)	)	)	N	O

Erythema	RB	erythema	erythema	erythema	Y	B-AdverseReaction
2	CD	2	2	2	N	O
(	(	(	(	(	N	O
5	CD	5	5	5	N	O
)	)	)	)	)	N	O

Vomiting	VBG	vomiting	vomiting	vomit	Y	B-AdverseReaction
2	CD	2	2	2	N	O
(	(	(	(	(	N	O
5	CD	5	5	5	N	O
)	)	)	)	)	N	O

Rigors	NNS	rigors	rigor	rigor	Y	B-AdverseReaction
2	CD	2	2	2	N	O
(	(	(	(	(	N	O
5	CD	5	5	5	N	O
)	)	)	)	)	N	O

Pallor	NN	pallor	pallor	pallor	Y	B-AdverseReaction
2	CD	2	2	2	N	O
(	(	(	(	(	N	O
5	CD	5	5	5	N	O
)	)	)	)	)	N	O

Cyanosis	NN	cyanosis	cyanosis	cyanosi	Y	B-AdverseReaction
2	CD	2	2	2	N	O
(	(	(	(	(	N	O
5	CD	5	5	5	N	O
)	)	)	)	)	N	O

Agitation	NN	agitation	agitation	agit	Y	B-AdverseReaction
2	CD	2	2	2	N	O
(	(	(	(	(	N	O
5	CD	5	5	5	N	O
)	)	)	)	)	N	O

Tremor	NN	tremor	tremor	tremor	Y	B-AdverseReaction
2	CD	2	2	2	N	O
(	(	(	(	(	N	O
5	CD	5	5	5	N	O
)	)	)	)	)	N	O

An	DT	an	an	an	N	O
open	JJ	open	open	open	N	O
-	:	-	-	-	N	O
label	NN	label	label	label	N	O
,	,	,	,	,	N	O
single	JJ	single	single	singl	N	O
-	:	-	-	-	N	O
center	NN	center	center	center	N	O
trial	NN	trial	trial	trial	N	O
was	VBD	was	wa	wa	N	O
conducted	VBN	conducted	conducted	conduct	N	O
in	IN	in	in	in	N	O
18	CD	18	18	18	N	O
treatment	NN	treatment	treatment	treatment	N	O
-	:	-	-	-	N	O
naive	JJ	naive	naive	naiv	N	O
infantile	JJ	infantile	infantile	infantil	N	O
-	:	-	-	-	N	O
onset	NN	onset	onset	onset	N	O
Pompe	NNP	pompe	pompe	pomp	N	O
disease	NN	disease	disease	diseas	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
were	VBD	were	were	were	N	O
treated	VBN	treated	treated	treat	N	O
exclusively	RB	exclusively	exclusively	exclus	N	O
with	IN	with	with	with	N	O
alglucosidase	NN	alglucosidase	alglucosidase	alglucosidas	N	O
alfa	NN	alfa	alfa	alfa	N	O
.	.	.	.	.	N	O

Adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
observed	VBN	observed	observed	observ	N	O
in	IN	in	in	in	N	O
these	DT	these	these	these	N	O
patients	NNS	patients	patient	patient	N	O
were	VBD	were	were	were	N	O
similar	JJ	similar	similar	similar	N	O
to	TO	to	to	to	N	O
infantile	VB	infantile	infantile	infantil	N	O
-	:	-	-	-	N	O
onset	NN	onset	onset	onset	N	O
Pompe	NNP	pompe	pompe	pomp	N	O
disease	NN	disease	disease	diseas	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
received	VBD	received	received	receiv	N	O
alglucosidase	JJ	alglucosidase	alglucosidase	alglucosidas	N	O
alfa	NN	alfa	alfa	alfa	N	O
in	IN	in	in	in	N	O
other	JJ	other	other	other	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
.	.	.	.	.	N	O

Additional	JJ	additional	additional	addit	N	O

hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
infantile	JJ	infantile	infantile	infantil	N	O
-	:	-	-	-	N	O
onset	NN	onset	onset	onset	N	O
Pompe	NNP	pompe	pompe	pomp	N	O
disease	NN	disease	disease	diseas	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
in	IN	in	in	in	N	O
other	JJ	other	other	other	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
and	CC	and	and	and	N	O
expanded	VBD	expanded	expanded	expand	N	O
access	NN	access	access	access	N	O
programs	NNS	programs	program	program	N	O
with	IN	with	with	with	N	O
alglucosidase	NN	alglucosidase	alglucosidase	alglucosidas	N	O
alfa	NN	alfa	alfa	alfa	N	O
included	VBD	included	included	includ	N	O
livedo	JJ	livedo	livedo	livedo	N	B-AdverseReaction
reticularis	NN	reticularis	reticularis	reticulari	N	I-AdverseReaction
,	,	,	,	,	N	O
irritability	NN	irritability	irritability	irrit	Y	B-AdverseReaction
,	,	,	,	,	N	O
retching	VBG	retching	retching	retch	Y	B-AdverseReaction
,	,	,	,	,	N	O
increased	JJ	increased	increased	increas	N	B-AdverseReaction
lacrimation	NN	lacrimation	lacrimation	lacrim	Y	I-AdverseReaction
,	,	,	,	,	N	O
ventricular	JJ	ventricular	ventricular	ventricular	N	B-AdverseReaction
extrasystoles	NNS	extrasystoles	extrasystole	extrasystol	Y	I-AdverseReaction
,	,	,	,	,	N	O
nodal	JJ	nodal	nodal	nodal	N	B-AdverseReaction
rhythm	NN	rhythm	rhythm	rhythm	N	I-AdverseReaction
,	,	,	,	,	N	O
rales	NNS	rales	rale	rale	Y	B-AdverseReaction
,	,	,	,	,	N	O
respiratory	NN	respiratory	respiratory	respiratori	N	B-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
irritation	NN	irritation	irritation	irrit	N	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
cold	JJ	cold	cold	cold	Y	B-AdverseReaction
sweat	NN	sweat	sweat	sweat	N	I-AdverseReaction
.	.	.	.	.	N	O

Safety	NN	safety	safety	safeti	N	O
was	VBD	was	wa	wa	N	O
also	RB	also	also	also	N	O
evaluated	VBN	evaluated	evaluated	evalu	N	O
in	IN	in	in	in	N	O
99	CD	99	99	99	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
51	CD	51	51	51	N	O
male	NN	male	male	male	N	O
,	,	,	,	,	N	O
48	CD	48	48	48	N	O
females	NNS	females	female	femal	N	O
)	)	)	)	)	N	O
with	IN	with	with	with	N	O
Pompe	NNP	pompe	pompe	pomp	N	O
disease	NN	disease	disease	diseas	N	O
in	IN	in	in	in	N	O
an	DT	an	an	an	N	O
ongoing	NN	ongoing	ongoing	ongo	N	O
,	,	,	,	,	N	O
open	JJ	open	open	open	N	O
-	:	-	-	-	N	O
label	NN	label	label	label	N	O
,	,	,	,	,	N	O
prospective	JJ	prospective	prospective	prospect	N	O
study	NN	study	study	studi	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
12	CD	12	12	12	N	O
months	NNS	months	month	month	N	O
of	IN	of	of	of	N	O
age	NN	age	age	age	N	O
and	CC	and	and	and	N	O
older	JJR	older	older	older	N	O
who	WP	who	who	who	N	O
were	VBD	were	were	were	N	O
previously	RB	previously	previously	previous	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
160	CD	160	160	160	N	O
L	NNP	l	l	l	N	O
scale	NN	scale	scale	scale	N	O
of	IN	of	of	of	N	O
alglucosidase	NN	alglucosidase	alglucosidase	alglucosidas	N	O
alfa	NN	alfa	alfa	alfa	N	O
and	CC	and	and	and	N	O
switched	VBD	switched	switched	switch	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
4000	CD	4000	4000	4000	N	O
L	NNP	l	l	l	N	O
scale	NN	scale	scale	scale	N	O
of	IN	of	of	of	N	O
alglucosidase	NN	alglucosidase	alglucosidase	alglucosidas	N	O
alfa	NN	alfa	alfa	alfa	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
were	VBD	were	were	were	N	O
aged	VBN	aged	aged	age	N	O
1	CD	1	1	1	N	O
to	TO	to	to	to	N	O
18	CD	18	18	18	N	O
years	NNS	years	year	year	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
median	JJ	median	median	median	N	O
duration	NN	duration	duration	durat	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
of	IN	of	of	of	N	O
437	CD	437	437	437	N	O
days	NNS	days	day	day	N	O
(	(	(	(	(	N	O
range	VB	range	range	rang	N	O
13	CD	13	13	13	N	O
to	TO	to	to	to	N	O
466	CD	466	466	466	N	O
days	NNS	days	day	day	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

No	DT	no	no	no	N	O
new	JJ	new	new	new	N	O
safety	NN	safety	safety	safeti	N	O
findings	NNS	findings	finding	find	N	O
were	VBD	were	were	were	N	O
observed	VBN	observed	observed	observ	N	O
following	VBG	following	following	follow	N	O
the	DT	the	the	the	N	O
switch	NN	switch	switch	switch	N	O
to	TO	to	to	to	N	O
4000	CD	4000	4000	4000	N	O
L	NNP	l	l	l	N	O
scale	NN	scale	scale	scale	N	O
of	IN	of	of	of	N	O
alglucosidase	NN	alglucosidase	alglucosidase	alglucosidas	N	O
alfa	NN	alfa	alfa	alfa	N	O
.	.	.	.	.	N	O

Clinical	JJ	clinical	clinical	clinic	N	O
Trials	NNS	trials	trial	trial	N	O
in	IN	in	in	in	N	O
Late	JJ	late	late	late	N	O
-	:	-	-	-	N	O
Onset	NNP	onset	onset	onset	N	O
Pompe	NNP	pompe	pompe	pomp	N	O
Disease	NNP	disease	disease	diseas	N	O

Assessment	NN	assessment	assessment	assess	N	O
of	IN	of	of	of	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
late	JJ	late	late	late	N	O
-	:	-	-	-	N	O
onset	NN	onset	onset	onset	N	O
Pompe	NNP	pompe	pompe	pomp	N	O
disease	NN	disease	disease	diseas	N	O
is	VBZ	is	is	is	N	O
based	VBN	based	based	base	N	O
on	IN	on	on	on	N	O
the	DT	the	the	the	N	O
exposure	NN	exposure	exposure	exposur	N	O
of	IN	of	of	of	N	O
90	CD	90	90	90	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
45	CD	45	45	45	N	O
male	NN	male	male	male	N	O
,	,	,	,	,	N	O
45	CD	45	45	45	N	O
female	NN	female	female	femal	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
aged	VBD	aged	aged	age	N	O
10	CD	10	10	10	N	O
to	TO	to	to	to	N	O
70	CD	70	70	70	N	O
years	NNS	years	year	year	N	O
,	,	,	,	,	N	O
to	TO	to	to	to	N	O
20	CD	20	20	20	N	O
mg	NNS	mg	mg	mg	N	O
kg	JJ	kg	kg	kg	N	O
alglucosidase	JJ	alglucosidase	alglucosidase	alglucosidas	N	O
alfa	NN	alfa	alfa	alfa	N	O
or	CC	or	or	or	N	O
placebo	NN	placebo	placebo	placebo	N	O
in	IN	in	in	in	N	O
a	DT	a	a	a	N	O
randomized	JJ	randomized	randomized	random	N	O
,	,	,	,	,	N	O
double	JJ	double	double	doubl	N	O
-	:	-	-	-	N	O
blind	NN	blind	blind	blind	Y	O
,	,	,	,	,	N	O
placebo	SYM	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
trial	NN	trial	trial	trial	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
youngest	JJS	youngest	youngest	youngest	N	O
alglucosidase	NN	alglucosidase	alglucosidase	alglucosidas	N	O
alfa	SYM	alfa	alfa	alfa	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patient	NN	patient	patient	patient	N	O
was	VBD	was	wa	wa	N	O
16	CD	16	16	16	N	O
years	NNS	years	year	year	N	O
of	IN	of	of	of	N	O
age	NN	age	age	age	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
the	DT	the	the	the	N	O
youngest	JJS	youngest	youngest	youngest	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patient	NN	patient	patient	patient	N	O
was	VBD	was	wa	wa	N	O
10	CD	10	10	10	N	O
years	NNS	years	year	year	N	O
of	IN	of	of	of	N	O
age	NN	age	age	age	N	O
.	.	.	.	.	N	O

All	DT	all	all	all	N	O
patients	NNS	patients	patient	patient	N	O
were	VBD	were	were	were	N	O
naive	JJ	naive	naive	naiv	N	O
to	TO	to	to	to	N	O
enzyme	VB	enzyme	enzyme	enzym	N	O
replacement	NN	replacement	replacement	replac	N	O
therapy	NN	therapy	therapy	therapi	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
were	VBD	were	were	were	N	O
randomized	VBN	randomized	randomized	random	N	O
in	IN	in	in	in	N	O
a	DT	a	a	a	N	O
2	CD	2	2	2	N	O
:	:	:	:	:	N	O
1	CD	1	1	1	N	O
ratio	NN	ratio	ratio	ratio	N	O
and	CC	and	and	and	N	O
received	VBD	received	received	receiv	N	O
alglucosidase	JJ	alglucosidase	alglucosidase	alglucosidas	N	O
alfa	NN	alfa	alfa	alfa	N	O
or	CC	or	or	or	N	O
placebo	NN	placebo	placebo	placebo	N	O
every	DT	every	every	everi	N	O
other	JJ	other	other	other	N	O
week	NN	week	week	week	N	O
for	IN	for	for	for	N	O
78	CD	78	78	78	N	O
weeks	NNS	weeks	week	week	N	O
(	(	(	(	(	N	O
18	CD	18	18	18	N	O
months	NNS	months	month	month	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
study	NN	study	study	studi	N	O
population	NN	population	population	popul	N	O
included	VBD	included	included	includ	N	O
34	CD	34	34	34	N	O
males	NNS	males	male	male	N	O
and	CC	and	and	and	N	O
26	CD	26	26	26	N	O
females	NNS	females	female	femal	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
60	CD	60	60	60	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
alglucosidase	NN	alglucosidase	alglucosidase	alglucosidas	N	O
alfa	NN	alfa	alfa	alfa	N	O
group	NN	group	group	group	N	O
and	CC	and	and	and	N	O
11	CD	11	11	11	N	O
males	NNS	males	male	male	N	O
and	CC	and	and	and	N	O
19	CD	19	19	19	N	O
females	NNS	females	female	femal	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
30	CD	30	30	30	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	O
group	NN	group	group	group	N	O
.	.	.	.	.	N	O

Two	CD	two	two	two	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
alglucosidase	NN	alglucosidase	alglucosidase	alglucosidas	N	O
alfa	NN	alfa	alfa	alfa	N	O
discontinued	VBD	discontinued	discontinued	discontinu	N	O
the	DT	the	the	the	N	O
trial	NN	trial	trial	trial	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
anaphylactic	JJ	anaphylactic	anaphylactic	anaphylact	N	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
.	.	.	.	.	N	O

Serious	JJ	serious	serious	seriou	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
reported	VBN	reported	reported	report	N	O
with	IN	with	with	with	N	O
alglucosidase	NN	alglucosidase	alglucosidase	alglucosidas	N	O
alfa	NN	alfa	alfa	alfa	N	O
included	VBD	included	included	includ	N	O
anaphylaxis	NN	anaphylaxis	anaphylaxis	anaphylaxi	Y	B-AdverseReaction
,	,	,	,	,	N	O
which	WDT	which	which	which	N	O
presented	VBD	presented	presented	present	N	O
as	IN	as	a	as	N	O
angioedema	NN	angioedema	angioedema	angioedema	Y	B-AdverseReaction
,	,	,	,	,	N	O
throat	NN	throat	throat	throat	N	B-AdverseReaction
tightness	NN	tightness	tightness	tight	N	I-AdverseReaction
and	CC	and	and	and	N	O
chest	NN	chest	chest	chest	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
discomfort	NN	discomfort	discomfort	discomfort	Y	I-AdverseReaction
.	.	.	.	.	N	O

One	CD	one	one	one	N	O
patient	NN	patient	patient	patient	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
Wolff	NNP	wolff	wolff	wolff	N	O
-	:	-	-	-	N	O
Parkinson	NNP	parkinson	parkinson	parkinson	N	O
-	:	-	-	-	N	O
White	NNP	white	white	white	N	O
syndrome	NN	syndrome	syndrome	syndrom	N	O
experienced	VBD	experienced	experienced	experienc	N	O
a	DT	a	a	a	N	O
serious	JJ	serious	serious	seriou	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
of	IN	of	of	of	N	O
supraventricular	JJ	supraventricular	supraventricular	supraventricular	N	B-AdverseReaction
tachycardia	NN	tachycardia	tachycardia	tachycardia	Y	I-AdverseReaction
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
3%	CD	3%	3%	3%	N	O
;	:	;	;	;	N	O
2	CD	2	2	2	N	O
or	CC	or	or	or	N	O
more	JJR	more	more	more	N	O
patients	NNS	patients	patient	patient	N	O
)	)	)	)	)	N	O
observed	VBN	observed	observed	observ	N	O
in	IN	in	in	in	N	O
alglucosidase	NN	alglucosidase	alglucosidase	alglucosidas	N	O
alfa	NN	alfa	alfa	alfa	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
were	VBD	were	were	were	N	O
hypersensitivity	JJ	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
and	CC	and	and	and	N	O
included	VBD	included	included	includ	N	O
anaphylaxis	NN	anaphylaxis	anaphylaxis	anaphylaxi	Y	B-AdverseReaction
,	,	,	,	,	N	O
headache	NN	headache	headache	headach	Y	B-AdverseReaction
,	,	,	,	,	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
,	,	,	,	,	N	O
urticaria	NN	urticaria	urticaria	urticaria	Y	B-AdverseReaction
,	,	,	,	,	N	O
dizziness	NN	dizziness	dizziness	dizzi	Y	B-AdverseReaction
,	,	,	,	,	N	O
chest	NN	chest	chest	chest	N	B-AdverseReaction
discomfort	NN	discomfort	discomfort	discomfort	Y	I-AdverseReaction
,	,	,	,	,	N	O
vomiting	VBG	vomiting	vomiting	vomit	Y	B-AdverseReaction
,	,	,	,	,	N	O
hyperhidrosis	NN	hyperhidrosis	hyperhidrosis	hyperhidrosi	Y	B-AdverseReaction
,	,	,	,	,	N	O
flushing	VBG	flushing	flushing	flush	Y	B-AdverseReaction
feeling	VBG	feeling	feeling	feel	N	B-AdverseReaction
hot	JJ	hot	hot	hot	N	I-AdverseReaction
,	,	,	,	,	N	O
increased	VBD	increased	increased	increas	N	B-AdverseReaction
blood	NN	blood	blood	blood	N	I-AdverseReaction
pressure	NN	pressure	pressure	pressur	N	I-AdverseReaction
,	,	,	,	,	N	O
paresthesia	NN	paresthesia	paresthesia	paresthesia	Y	B-AdverseReaction
,	,	,	,	,	N	O
pyrexia	NN	pyrexia	pyrexia	pyrexia	Y	B-AdverseReaction
,	,	,	,	,	N	O
local	JJ	local	local	local	N	B-AdverseReaction
swelling	NN	swelling	swelling	swell	Y	I-AdverseReaction
,	,	,	,	,	N	O
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
,	,	,	,	,	N	O
pruritus	NN	pruritus	pruritus	pruritu	Y	B-AdverseReaction
,	,	,	,	,	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
throat	NN	throat	throat	throat	N	B-AdverseReaction
tightness	NN	tightness	tightness	tight	N	I-AdverseReaction
.	.	.	.	.	N	O

Delayed	NNP	delayed	delayed	delay	N	O
-	:	-	-	-	N	O
onset	NN	onset	onset	onset	N	O
reactions	NNS	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
defined	VBD	defined	defined	defin	N	O
as	IN	as	a	as	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
occurring	VBG	occurring	occurring	occur	N	O
2	CD	2	2	2	N	O
-	:	-	-	-	N	O
48	CD	48	48	48	N	O
hours	NNS	hours	hour	hour	N	O
after	IN	after	after	after	N	O
completion	NN	completion	completion	complet	N	O
of	IN	of	of	of	N	O
alglucosidase	NN	alglucosidase	alglucosidase	alglucosidas	N	O
alfa	NN	alfa	alfa	alfa	N	O
infusion	NN	infusion	infusion	infus	Y	O
,	,	,	,	,	N	O
that	WDT	that	that	that	N	O
were	VBD	were	were	were	N	O
observed	VBN	observed	observed	observ	N	O
in	IN	in	in	in	N	O
3%	CD	3%	3%	3%	N	O
more	JJR	more	more	more	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
alglucosidase	NN	alglucosidase	alglucosidase	alglucosidas	N	O
alfa	SYM	alfa	alfa	alfa	N	O
-	:	-	-	-	N	O
treated	VBN	treated	treated	treat	N	O
group	NN	group	group	group	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
treated	VBN	treated	treated	treat	N	O
group	NN	group	group	group	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
controlled	JJ	controlled	controlled	control	N	O
trial	NN	trial	trial	trial	N	O
,	,	,	,	,	N	O
included	VBD	included	included	includ	N	O
hyperhidrosis	NN	hyperhidrosis	hyperhidrosis	hyperhidrosi	Y	B-AdverseReaction
.	.	.	.	.	N	O

Additional	NNP	additional	additional	addit	N	O
delayed	VBD	delayed	delayed	delay	N	O
-	:	-	-	-	N	O
onset	NN	onset	onset	onset	N	O
reactions	NNS	reactions	reaction	reaction	N	O
occurring	VBG	occurring	occurring	occur	N	O
in	IN	in	in	in	N	O
alglucosidase	NN	alglucosidase	alglucosidase	alglucosidas	N	O
alfa	NN	alfa	alfa	alfa	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
included	VBD	included	included	includ	N	O
fatigue	NN	fatigue	fatigue	fatigu	Y	B-AdverseReaction
,	,	,	,	,	N	O
myalgia	NN	myalgia	myalgia	myalgia	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
counseled	VBN	counseled	counseled	counsel	N	O
about	IN	about	about	about	N	O
the	DT	the	the	the	N	O
possibility	NN	possibility	possibility	possibl	N	O
of	IN	of	of	of	N	O
delayed	JJ	delayed	delayed	delay	N	O
-	:	-	-	-	N	O
onset	NN	onset	onset	onset	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	O
reactions	NNS	reactions	reaction	reaction	N	O
and	CC	and	and	and	N	O
given	VBN	given	given	given	N	O
proper	JJ	proper	proper	proper	N	O
follow	SYM	follow	follow	follow	N	O
-	:	-	-	-	N	O
up	RP	up	up	up	N	O
instructions	NNS	instructions	instruction	instruct	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
3	CD	3	3	3	N	O
summarizes	VBZ	summarizes	summarizes	summar	N	O
the	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
that	WDT	that	that	that	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
3%	CD	3%	3%	3%	N	O
of	IN	of	of	of	N	O
alglucosidase	NN	alglucosidase	alglucosidase	alglucosidas	N	O
alfa	SYM	alfa	alfa	alfa	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
and	CC	and	and	and	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
higher	JJR	higher	higher	higher	N	O
incidence	NN	incidence	incidence	incid	N	O
than	IN	than	than	than	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
during	IN	during	during	dure	N	O
the	DT	the	the	the	N	O
randomized	VBN	randomized	randomized	random	N	O
,	,	,	,	,	N	O
double	JJ	double	double	doubl	N	O
-	:	-	-	-	N	O
blind	NN	blind	blind	blind	Y	O
,	,	,	,	,	N	O
placebo	SYM	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
study	NN	study	study	studi	N	O
described	VBN	described	described	describ	N	O
above	IN	above	above	abov	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
3	CD	3	3	3	N	O
:	:	:	:	:	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNS	reactions	reaction	reaction	N	O
Occurring	VBG	occurring	occurring	occur	N	O
in	IN	in	in	in	N	O
at	IN	at	at	at	N	O
Least	NNP	least	least	least	N	O
3%	CD	3%	3%	3%	N	O
of	IN	of	of	of	N	O
Alglucosidase	NNP	alglucosidase	alglucosidase	alglucosidas	N	O
Alfa	NNP	alfa	alfa	alfa	N	O
-	:	-	-	-	N	O
Treated	VBN	treated	treated	treat	N	O
Late	JJ	late	late	late	N	O
-	:	-	-	-	N	O
Onset	NN	onset	onset	onset	N	O
Patients	NNS	patients	patient	patient	N	O
and	CC	and	and	and	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
Higher	JJR	higher	higher	higher	N	O
Incidence	NN	incidence	incidence	incid	N	O
than	IN	than	than	than	N	O
the	DT	the	the	the	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
Treated	VBD	treated	treated	treat	N	O
Patients	NNS	patients	patient	patient	N	O

Adverse	JJ	adverse	adverse	advers	N	O
Reaction	NNP	reaction	reaction	reaction	N	O
Alglucosidase	NNP	alglucosidase	alglucosidase	alglucosidas	N	O
Alfan	NNP	alfan	alfan	alfan	N	O
60	CD	60	60	60	N	O
N	NNP	n	n	n	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
Placebon	NNP	placebon	placebon	placebon	N	O
30	CD	30	30	30	N	O
N	NNP	n	n	n	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O

Hyperhidrosis	NN	hyperhidrosis	hyperhidrosis	hyperhidrosi	Y	B-AdverseReaction

5	CD	5	5	5	N	O
(	(	(	(	(	N	O
8.3	CD	8.3	8.3	8.3	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O
(	(	(	(	(	N	O
0	CD	0	0	0	N	O
)	)	)	)	)	N	O

Urticaria	NNS	urticaria	urticaria	urticaria	Y	B-AdverseReaction
5	CD	5	5	5	N	O
(	(	(	(	(	N	O
8.3	CD	8.3	8.3	8.3	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O
(	(	(	(	(	N	O
0	CD	0	0	0	N	O
)	)	)	)	)	N	O

Anaphylaxis	$	anaphylaxis	anaphylaxis	anaphylaxi	Y	B-AdverseReaction
4	CD	4	4	4	N	O
(	(	(	(	(	N	O
6.7	CD	6.7	6.7	6.7	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O
(	(	(	(	(	N	O
0	CD	0	0	0	N	O
)	)	)	)	)	N	O

Chest	NNP	chest	chest	chest	N	B-AdverseReaction
Discomfort	NNP	discomfort	discomfort	discomfort	Y	I-AdverseReaction
4	CD	4	4	4	N	O
(	(	(	(	(	N	O
6.7	CD	6.7	6.7	6.7	N	O
)	)	)	)	)	N	O
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
3.3	CD	3.3	3.3	3.3	N	O
)	)	)	)	)	N	O

Muscle	NNP	muscle	muscle	muscl	N	B-AdverseReaction
Twitching	VBG	twitching	twitching	twitch	Y	I-AdverseReaction
4	CD	4	4	4	N	O
(	(	(	(	(	N	O
6.7	CD	6.7	6.7	6.7	N	O
)	)	)	)	)	N	O
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
3.3	CD	3.3	3.3	3.3	N	O
)	)	)	)	)	N	O

Myalgia	NNP	myalgia	myalgia	myalgia	Y	B-AdverseReaction
3	CD	3	3	3	N	O
(	(	(	(	(	N	O
5.0	CD	5.0	5.0	5.0	N	O
)	)	)	)	)	N	O
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
3.3	CD	3.3	3.3	3.3	N	O
)	)	)	)	)	N	O

Flushing	VBG	flushing	flushing	flush	Y	B-AdverseReaction
Feeling	VBG	feeling	feeling	feel	N	B-AdverseReaction
Hot	NNP	hot	hot	hot	N	I-AdverseReaction
3	CD	3	3	3	N	O
(	(	(	(	(	N	O
5.0	CD	5.0	5.0	5.0	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O
(	(	(	(	(	N	O
0	CD	0	0	0	N	O
)	)	)	)	)	N	O

Increased	VBN	increased	increased	increas	N	B-AdverseReaction
Blood	NNP	blood	blood	blood	N	I-AdverseReaction
Pressure	NN	pressure	pressure	pressur	N	I-AdverseReaction
3	CD	3	3	3	N	O
(	(	(	(	(	N	O
5.0	CD	5.0	5.0	5.0	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O
(	(	(	(	(	N	O
0	CD	0	0	0	N	O
)	)	)	)	)	N	O

Vomiting	VBG	vomiting	vomiting	vomit	Y	B-AdverseReaction
3	CD	3	3	3	N	O
(	(	(	(	(	N	O
5.0	CD	5.0	5.0	5.0	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O
(	(	(	(	(	N	O
0	CD	0	0	0	N	O
)	)	)	)	)	N	O

Edema	NNP	edema	edema	edema	Y	B-AdverseReaction
,	,	,	,	,	N	I-AdverseReaction
Peripheral	NNP	peripheral	peripheral	peripher	N	I-AdverseReaction
2	CD	2	2	2	N	O
(	(	(	(	(	N	O
3.3	CD	3.3	3.3	3.3	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O
(	(	(	(	(	N	O
0	CD	0	0	0	N	O
)	)	)	)	)	N	O

Pruritus	NN	pruritus	pruritus	pruritu	Y	B-AdverseReaction
2	CD	2	2	2	N	O
(	(	(	(	(	N	O
3.3	CD	3.3	3.3	3.3	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O
(	(	(	(	(	N	O
0	CD	0	0	0	N	O
)	)	)	)	)	N	O

Rash	NNP	rash	rash	rash	Y	B-AdverseReaction
Papular	NNP	papular	papular	papular	N	I-AdverseReaction
2	CD	2	2	2	N	O
(	(	(	(	(	N	O
3.3	CD	3.3	3.3	3.3	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O
(	(	(	(	(	N	O
0	CD	0	0	0	N	O
)	)	)	)	)	N	O

Throat	NNP	throat	throat	throat	N	B-AdverseReaction
Tightness	NNP	tightness	tightness	tight	N	I-AdverseReaction
2	CD	2	2	2	N	O
(	(	(	(	(	N	O
3.3	CD	3.3	3.3	3.3	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O
(	(	(	(	(	N	O
0	CD	0	0	0	N	O
)	)	)	)	)	N	O

In	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
anaphylaxis	NN	anaphylaxis	anaphylaxis	anaphylaxi	Y	B-AdverseReaction
and	CC	and	and	and	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
were	VBD	were	were	were	N	O
managed	VBN	managed	managed	manag	N	O
with	IN	with	with	with	N	O
infusion	NN	infusion	infusion	infus	Y	O
interruption	NN	interruption	interruption	interrupt	N	O
,	,	,	,	,	N	O
decreased	VBN	decreased	decreased	decreas	N	O
infusion	NN	infusion	infusion	infus	Y	O
rate	NN	rate	rate	rate	N	O
,	,	,	,	,	N	O
administration	NN	administration	administration	administr	N	O
of	IN	of	of	of	N	O
antihistamines	NNS	antihistamines	antihistamine	antihistamin	N	O
,	,	,	,	,	N	O
corticosteroids	NNS	corticosteroids	corticosteroid	corticosteroid	N	O
,	,	,	,	,	N	O
intravenous	JJ	intravenous	intravenous	intraven	N	O
fluids	NNS	fluids	fluid	fluid	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
oxygen	NN	oxygen	oxygen	oxygen	N	O
,	,	,	,	,	N	O
when	WRB	when	when	when	N	O
clinically	RB	clinically	clinically	clinic	N	O
indicated	VBN	indicated	indicated	indic	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
some	DT	some	some	some	N	O
cases	NNS	cases	case	case	N	O
of	IN	of	of	of	N	O
anaphylactic	JJ	anaphylactic	anaphylactic	anaphylact	N	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
,	,	,	,	,	N	O
epinephrine	NN	epinephrine	epinephrine	epinephrin	Y	O
was	VBD	was	wa	wa	N	O
administered	VBN	administered	administered	administ	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
have	VBP	have	have	have	N	O
experienced	VBN	experienced	experienced	experienc	N	O
anaphylaxis	NN	anaphylaxis	anaphylaxis	anaphylaxi	Y	O
or	CC	or	or	or	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	O
reactions	NNS	reactions	reaction	reaction	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
caution	NN	caution	caution	caution	N	O
when	WRB	when	when	when	N	O
they	PRP	they	they	they	N	O
are	VBP	are	are	are	N	O
re	JJ	re	re	re	N	O
-	:	-	-	-	N	O
administered	JJ	administered	administered	administ	N	O
alglucosidase	NN	alglucosidase	alglucosidase	alglucosidas	N	O
alfa	NN	alfa	alfa	alfa	N	O
.	.	.	.	.	N	O

6.2	CD	6.2	6.2	6.2	N	O

Immunogenicity	NN	immunogenicity	immunogenicity	immunogen	N	O

As	IN	as	a	as	N	O
with	IN	with	with	with	N	O
all	DT	all	all	all	N	O
therapeutic	JJ	therapeutic	therapeutic	therapeut	N	O
proteins	NNS	proteins	protein	protein	N	O
,	,	,	,	,	N	O
there	EX	there	there	there	N	O
is	VBZ	is	is	is	N	O
potential	JJ	potential	potential	potenti	N	O
for	IN	for	for	for	N	O
immunogenicity	NN	immunogenicity	immunogenicity	immunogen	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
data	NNS	data	data	data	N	O
reflect	VBP	reflect	reflect	reflect	N	O
the	DT	the	the	the	N	O
percentage	NN	percentage	percentage	percentag	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
whose	WP$	whose	whose	whose	N	O
test	NN	test	test	test	N	O
results	NNS	results	result	result	N	O
were	VBD	were	were	were	N	O
considered	VBN	considered	considered	consid	N	O
positive	JJ	positive	positive	posit	N	O
for	IN	for	for	for	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
to	TO	to	to	to	N	O
alglucosidase	VB	alglucosidase	alglucosidase	alglucosidas	N	O
alfa	RP	alfa	alfa	alfa	N	O
using	VBG	using	using	use	N	O
an	DT	an	an	an	N	O
enzyme	JJ	enzyme	enzyme	enzym	N	O
-	:	-	-	-	N	O
linked	VBN	linked	linked	link	N	O
immunosorbent	JJ	immunosorbent	immunosorbent	immunosorb	N	O
assay	NN	assay	assay	assay	N	O
(	(	(	(	(	N	O
ELISA	NNP	elisa	elisa	elisa	Y	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
confirmed	VBN	confirmed	confirmed	confirm	N	O
by	IN	by	by	by	N	O
a	DT	a	a	a	N	O
radioimmunoprecipitation	NN	radioimmunoprecipitation	radioimmunoprecipitation	radioimmunoprecipit	N	O
(	(	(	(	(	N	O
RIP	NNP	rip	rip	rip	N	O
)	)	)	)	)	N	O
assay	VBP	assay	assay	assay	N	O
for	IN	for	for	for	N	O
alglucosidase	NN	alglucosidase	alglucosidase	alglucosidas	N	O
alfa	NN	alfa	alfa	alfa	N	O
-	:	-	-	-	N	O
specific	JJ	specific	specific	specif	N	O
IgG	NNP	igg	igg	igg	Y	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
two	CD	two	two	two	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
in	IN	in	in	in	N	O
infantile	JJ	infantile	infantile	infantil	N	O
-	:	-	-	-	N	O
onset	NN	onset	onset	onset	N	O
patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
majority	NN	majority	majority	major	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
34	CD	34	34	34	N	O
of	IN	of	of	of	N	O
38	CD	38	38	38	N	O
;	:	;	;	;	N	O
89%	CD	89%	89%	89%	N	O
)	)	)	)	)	N	O
tested	VBD	tested	tested	test	N	O
positive	JJ	positive	positive	posit	N	O
for	IN	for	for	for	N	O
IgG	NNP	igg	igg	igg	Y	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
to	TO	to	to	to	N	O
alglucosidase	VB	alglucosidase	alglucosidase	alglucosidas	N	O
alfa	NN	alfa	alfa	alfa	N	O
.	.	.	.	.	N	O

There	EX	there	there	there	N	O
is	VBZ	is	is	is	N	O
evidence	NN	evidence	evidence	evid	N	O
to	TO	to	to	to	N	O
suggest	VB	suggest	suggest	suggest	N	O
that	IN	that	that	that	N	O
some	DT	some	some	some	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
develop	VBP	develop	develop	develop	N	O
high	JJ	high	high	high	N	O
sustained	VBN	sustained	sustained	sustain	N	O
titers	NNS	titers	titer	titer	N	O
of	IN	of	of	of	N	O
anti	JJ	anti	anti	anti	N	O
-	:	-	-	-	N	O
alglucosidase	NN	alglucosidase	alglucosidase	alglucosidas	N	O
alfa	JJ	alfa	alfa	alfa	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
may	MD	may	may	may	N	O
experience	VB	experience	experience	experi	N	O
reduced	JJ	reduced	reduced	reduc	N	O
clinical	JJ	clinical	clinical	clinic	N	O
efficacy	NN	efficacy	efficacy	efficaci	N	O
to	TO	to	to	to	N	O
alglucosidase	VB	alglucosidase	alglucosidase	alglucosidas	N	O
alfa	JJ	alfa	alfa	alfa	N	O
treatment	NN	treatment	treatment	treatment	N	O
[	JJ	[	[	[	N	O
seeWarnings	NNS	seewarnings	seewarnings	seewarn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.5	CD	5.5	5.5	5.5	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Some	DT	some	some	some	N	O
IgG	NNP	igg	igg	igg	Y	O
-	:	-	-	-	N	O
positive	JJ	positive	positive	posit	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
who	WP	who	who	who	N	O
were	VBD	were	were	were	N	O
retrospectively	RB	retrospectively	retrospectively	retrospect	N	O
evaluated	VBN	evaluated	evaluated	evalu	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
presence	NN	presence	presence	presenc	N	O
of	IN	of	of	of	N	O
inhibitory	JJ	inhibitory	inhibitory	inhibitori	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
tested	VBD	tested	tested	test	N	O
positive	JJ	positive	positive	posit	N	O
for	IN	for	for	for	N	O
inhibition	NN	inhibition	inhibition	inhibit	N	O
of	IN	of	of	of	N	O
enzyme	JJ	enzyme	enzyme	enzym	N	O
activity	NN	activity	activity	activ	N	O
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
uptake	VB	uptake	uptake	uptak	N	O
in	IN	in	in	in	N	O
in	IN	in	in	in	N	O
vitro	NN	vitro	vitro	vitro	N	O
assays	NNS	assays	assay	assay	N	O
.	.	.	.	.	N	O

Furthermore	RB	furthermore	furthermore	furthermor	N	O
,	,	,	,	,	N	O
CRIM	NNP	crim	crim	crim	N	O
-	:	-	-	-	N	O
negative	JJ	negative	negative	neg	N	O
infants	NNS	infants	infant	infant	N	O
have	VBP	have	have	have	N	O
shown	VBN	shown	shown	shown	N	O
reduced	JJ	reduced	reduced	reduc	N	O
clinical	JJ	clinical	clinical	clinic	N	O
effect	NN	effect	effect	effect	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
presence	NN	presence	presence	presenc	N	O
of	IN	of	of	of	N	O
high	JJ	high	high	high	N	B-Severity
sustained	VBN	sustained	sustained	sustain	N	I-Severity
IgG	NNP	igg	igg	igg	Y	B-AdverseReaction
antibody	NN	antibody	antibody	antibodi	N	I-AdverseReaction
titers	NNS	titers	titer	titer	N	I-AdverseReaction
with	IN	with	with	with	N	I-AdverseReaction
inhibitory	JJ	inhibitory	inhibitory	inhibitori	N	I-AdverseReaction
activity	NN	activity	activity	activ	N	I-AdverseReaction
.	.	.	.	.	N	O

Alglucosidase	NNP	alglucosidase	alglucosidase	alglucosidas	N	O
alfa	SYM	alfa	alfa	alfa	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
experience	VBP	experience	experience	experi	N	O
a	DT	a	a	a	N	O
decrease	NN	decrease	decrease	decreas	N	O
in	IN	in	in	in	N	O
motor	NN	motor	motor	motor	N	O
function	NN	function	function	function	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
tested	VBN	tested	tested	test	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
presence	NN	presence	presence	presenc	N	O
of	IN	of	of	of	N	O
inhibitory	JJ	inhibitory	inhibitory	inhibitori	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
that	WDT	that	that	that	N	O
neutralize	VBP	neutralize	neutralize	neutral	N	O
enzyme	JJ	enzyme	enzyme	enzym	N	O
uptake	NN	uptake	uptake	uptak	N	O
or	CC	or	or	or	N	O
activity	NN	activity	activity	activ	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
randomized	NN	randomized	randomized	random	N	O
,	,	,	,	,	N	O
double	JJ	double	double	doubl	N	O
-	:	-	-	-	N	O
blind	NN	blind	blind	blind	Y	O
,	,	,	,	,	N	O
placebo	SYM	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
trial	NN	trial	trial	trial	N	O
in	IN	in	in	in	N	O
late	JJ	late	late	late	N	O
-	:	-	-	-	N	O
onset	NN	onset	onset	onset	N	O
patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
all	DT	all	all	all	N	O
alglucosidase	NN	alglucosidase	alglucosidase	alglucosidas	N	O
alfa	SYM	alfa	alfa	alfa	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
available	JJ	available	available	avail	N	O
samples	NNS	samples	sample	sampl	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
59	CD	59	59	59	N	O
,	,	,	,	,	N	O
100%	CD	100%	100%	100%	N	O
)	)	)	)	)	N	O
developed	VBD	developed	developed	develop	N	O
IgG	NNP	igg	igg	igg	Y	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
to	TO	to	to	to	N	O
alglucosidase	VB	alglucosidase	alglucosidase	alglucosidas	N	O
alfa	NN	alfa	alfa	alfa	N	O
.	.	.	.	.	N	O

Most	JJS	most	most	most	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
developed	VBD	developed	developed	develop	N	O
IgG	NNP	igg	igg	igg	Y	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
did	VBD	did	did	did	N	O
so	RB	so	so	so	N	O
within	IN	within	within	within	N	O
the	DT	the	the	the	N	O
first	JJ	first	first	first	N	O
3	CD	3	3	3	N	O
months	NNS	months	month	month	N	O
of	IN	of	of	of	N	O
exposure	NN	exposure	exposure	exposur	N	O
(	(	(	(	(	N	O
median	JJ	median	median	median	N	O
time	NN	time	time	time	N	O
to	TO	to	to	to	N	O
seroconversion	NN	seroconversion	seroconversion	seroconvers	N	O
was	VBD	was	wa	wa	N	O
4	CD	4	4	4	N	O
weeks	NNS	weeks	week	week	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

There	EX	there	there	there	N	O
was	VBD	was	wa	wa	N	O
no	DT	no	no	no	N	O
apparent	JJ	apparent	apparent	appar	N	O
association	NN	association	association	associ	N	O
between	IN	between	between	between	N	O
mean	NN	mean	mean	mean	N	O
or	CC	or	or	or	N	O
peak	VB	peak	peak	peak	N	O
IgG	NNP	igg	igg	igg	Y	O
antibody	NN	antibody	antibody	antibodi	N	O
titers	NNS	titers	titer	titer	N	O
and	CC	and	and	and	N	O
the	DT	the	the	the	N	O
occurrence	NN	occurrence	occurrence	occurr	N	O
of	IN	of	of	of	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
.	.	.	.	.	N	O

None	NN	none	none	none	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
59	CD	59	59	59	N	O
evaluable	JJ	evaluable	evaluable	evalu	N	O
patients	NNS	patients	patient	patient	N	O
tested	VBD	tested	tested	test	N	O
positive	JJ	positive	positive	posit	N	O
for	IN	for	for	for	N	O
inhibition	NN	inhibition	inhibition	inhibit	N	O
of	IN	of	of	of	N	O
enzyme	JJ	enzyme	enzyme	enzym	N	O
activity	NN	activity	activity	activ	N	O
.	.	.	.	.	N	O

Antibody	NN	antibody	antibody	antibodi	N	O
titers	NNS	titers	titer	titer	N	O
for	IN	for	for	for	N	O
cellular	JJ	cellular	cellular	cellular	N	O
uptake	JJ	uptake	uptake	uptak	N	O
inhibition	NN	inhibition	inhibition	inhibit	N	O
were	VBD	were	were	were	N	O
present	JJ	present	present	present	N	O
in	IN	in	in	in	N	O
18	CD	18	18	18	N	O
of	IN	of	of	of	N	O
59	CD	59	59	59	N	O
(	(	(	(	(	N	O
31%	CD	31%	31%	31%	N	O
)	)	)	)	)	N	O
patients	NNS	patients	patient	patient	N	O
by	IN	by	by	by	N	O
Week	JJ	week	week	week	N	O
78	CD	78	78	78	N	O
.	.	.	.	.	N	O

All	DT	all	all	all	N	O
other	JJ	other	other	other	N	O
patients	NNS	patients	patient	patient	N	O
tested	VBN	tested	tested	test	N	O
negative	JJ	negative	negative	neg	N	O
for	IN	for	for	for	N	O
inhibition	NN	inhibition	inhibition	inhibit	N	O
of	IN	of	of	of	N	O
cellular	JJ	cellular	cellular	cellular	N	O
uptake	NN	uptake	uptake	uptak	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
tested	VBD	tested	tested	test	N	O
positive	JJ	positive	positive	posit	N	O
for	IN	for	for	for	N	O
uptake	JJ	uptake	uptake	uptak	N	O
inhibition	NN	inhibition	inhibition	inhibit	N	O
tended	VBD	tended	tended	tend	N	O
to	TO	to	to	to	N	O
have	VB	have	have	have	N	O
higher	JJR	higher	higher	higher	N	O
IgG	NNP	igg	igg	igg	Y	O
titers	NNS	titers	titer	titer	N	O
than	IN	than	than	than	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
tested	VBD	tested	tested	test	N	O
negative	JJ	negative	negative	neg	N	O
for	IN	for	for	for	N	O
uptake	JJ	uptake	uptake	uptak	N	O
inhibition	NN	inhibition	inhibition	inhibit	N	O
.	.	.	.	.	N	O

Among	IN	among	among	among	N	O
the	DT	the	the	the	N	O
32	CD	32	32	32	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
evaluable	JJ	evaluable	evaluable	evalu	N	O
pharmacokinetic	JJ	pharmacokinetic	pharmacokinetic	pharmacokinet	N	O
(	(	(	(	(	N	O
PK	NNP	pk	pk	pk	N	O
)	)	)	)	)	N	O
samples	NNS	samples	sample	sampl	N	O
,	,	,	,	,	N	O
5	CD	5	5	5	N	O
patients	NNS	patients	patient	patient	N	O
tested	VBD	tested	tested	test	N	O
positive	JJ	positive	positive	posit	N	O
for	IN	for	for	for	N	O
uptake	JJ	uptake	uptake	uptak	N	O
inhibition	NN	inhibition	inhibition	inhibit	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
relevance	NN	relevance	relevance	relev	N	O
of	IN	of	of	of	N	O
this	DT	this	this	thi	N	O
in	IN	in	in	in	N	O
vitro	JJ	vitro	vitro	vitro	N	O
inhibition	NN	inhibition	inhibition	inhibit	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
fully	RB	fully	fully	fulli	N	O
understood	JJ	understood	understood	understood	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
clearance	NN	clearance	clearance	clearanc	N	O
values	NNS	values	value	valu	N	O
for	IN	for	for	for	N	O
4	CD	4	4	4	N	O
of	IN	of	of	of	N	O
these	DT	these	these	these	N	O
5	CD	5	5	5	N	O
patients	NNS	patients	patient	patient	N	O
were	VBD	were	were	were	N	O
approximately	RB	approximately	approximately	approxim	N	O
1.2	CD	1.2	1.2	1.2	N	O
-	:	-	-	-	N	O
to	TO	to	to	to	N	O
1.8	CD	1.8	1.8	1.8	N	O
-	:	-	-	-	N	O
fold	NN	fold	fold	fold	N	O
greater	JJR	greater	greater	greater	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
presence	NN	presence	presence	presenc	N	O
of	IN	of	of	of	N	O
inhibitory	JJ	inhibitory	inhibitory	inhibitori	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
(	(	(	(	(	N	O
Week	NNP	week	week	week	N	O
52	RB	52	52	52	N	O
)	)	)	)	)	N	O
as	IN	as	a	as	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
absence	NN	absence	absence	absenc	N	O
of	IN	of	of	of	N	O
inhibitory	JJ	inhibitory	inhibitory	inhibitori	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
(	(	(	(	(	N	O
Week	NNP	week	week	week	N	O
0	CD	0	0	0	N	O
)	)	)	)	)	N	O
[	FW	[	[	[	N	O
seeClinical	JJ	seeclinical	seeclinical	seeclin	N	O
Pharmacology	NNP	pharmacology	pharmacology	pharmacolog	N	O
(	(	(	(	(	N	O
12.3	CD	12.3	12.3	12.3	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Some	DT	some	some	some	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
studies	NNS	studies	study	studi	N	O
or	CC	or	or	or	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
postmarketing	NN	postmarketing	postmarketing	postmarket	N	O
setting	VBG	setting	setting	set	N	O
have	VBP	have	have	have	N	O
undergone	JJ	undergone	undergone	undergon	N	O
testing	VBG	testing	testing	test	N	O
for	IN	for	for	for	N	O
alglucosidase	NN	alglucosidase	alglucosidase	alglucosidas	N	O
alfa	NN	alfa	alfa	alfa	N	O
-	:	-	-	-	N	O
specific	JJ	specific	specific	specif	N	O
IgE	NNP	ige	ige	ige	Y	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
.	.	.	.	.	N	O

Testing	VBG	testing	testing	test	N	O
was	VBD	was	wa	wa	N	O
performed	VBN	performed	performed	perform	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
experienced	VBD	experienced	experienced	experienc	N	O
moderate	JJ	moderate	moderate	moder	N	B-Severity
to	TO	to	to	to	N	I-Severity
severe	VB	severe	severe	sever	N	I-Severity
or	CC	or	or	or	N	O
recurrent	VB	recurrent	recurrent	recurr	N	B-AdverseReaction
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	I-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
,	,	,	,	,	N	O
for	IN	for	for	for	N	O
which	WDT	which	which	which	N	O
mast	JJS	mast	mast	mast	N	O
-	:	-	-	-	N	O
cell	NN	cell	cell	cell	N	O
activation	NN	activation	activation	activ	N	O
was	VBD	was	wa	wa	N	O
suspected	VBN	suspected	suspected	suspect	N	O
.	.	.	.	.	N	O

Some	DT	some	some	some	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
tested	VBD	tested	tested	test	N	O
positive	JJ	positive	positive	posit	N	O
for	IN	for	for	for	N	O
alglucosidase	NN	alglucosidase	alglucosidase	alglucosidas	N	O
alfa	NN	alfa	alfa	alfa	N	O
-	:	-	-	-	N	O
specific	JJ	specific	specific	specif	N	O
IgE	NNP	ige	ige	ige	Y	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
experienced	VBD	experienced	experienced	experienc	N	O
anaphylactic	JJ	anaphylactic	anaphylactic	anaphylact	N	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
[	VBP	[	[	[	N	O
seeBoxed	JJ	seeboxed	seeboxed	seebox	N	O
WarningandWarnings	NNS	warningandwarnings	warningandwarnings	warningandwarn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Some	DT	some	some	some	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
tested	VBD	tested	tested	test	N	O
positive	JJ	positive	positive	posit	N	O
for	IN	for	for	for	N	O
alglucosidase	NN	alglucosidase	alglucosidase	alglucosidas	N	O
alfa	NN	alfa	alfa	alfa	N	O
-	:	-	-	-	N	O
specific	JJ	specific	specific	specif	N	O
IgE	NNP	ige	ige	ige	Y	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
and	CC	and	and	and	N	O
experienced	JJ	experienced	experienced	experienc	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
were	VBD	were	were	were	N	O
able	JJ	able	able	abl	N	O
to	TO	to	to	to	N	O
be	VB	be	be	be	N	O
rechallenged	VBN	rechallenged	rechallenged	rechalleng	N	O
with	IN	with	with	with	N	O
alglucosidase	NN	alglucosidase	alglucosidase	alglucosidas	N	O
alfa	NN	alfa	alfa	alfa	N	O
using	VBG	using	using	use	N	O
a	DT	a	a	a	N	O
slower	JJR	slower	slower	slower	N	O
infusion	NN	infusion	infusion	infus	Y	O
rate	NN	rate	rate	rate	N	O
at	IN	at	at	at	N	O
lower	JJR	lower	lower	lower	N	O
starting	NN	starting	starting	start	N	O
doses	NNS	doses	dos	dose	N	O
and	CC	and	and	and	N	O
have	VBP	have	have	have	N	O
continued	VBN	continued	continued	continu	N	O
to	TO	to	to	to	N	O
receive	VB	receive	receive	receiv	N	O
treatment	NN	treatment	treatment	treatment	N	O
under	IN	under	under	under	N	O
close	JJ	close	close	close	N	O
clinical	JJ	clinical	clinical	clinic	N	O
supervision	NN	supervision	supervision	supervis	N	O
[	NNP	[	[	[	N	O
seeWarnings	NNS	seewarnings	seewarnings	seewarn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Since	IN	since	since	sinc	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
develop	VBP	develop	develop	develop	N	O
IgE	NNP	ige	ige	ige	Y	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
to	TO	to	to	to	N	O
alglucosidase	VB	alglucosidase	alglucosidase	alglucosidas	N	O
alfa	RB	alfa	alfa	alfa	N	O
appear	VB	appear	appear	appear	N	O
to	TO	to	to	to	N	O
be	VB	be	be	be	N	O
at	IN	at	at	at	N	O
a	DT	a	a	a	N	O
higher	JJR	higher	higher	higher	N	O
risk	NN	risk	risk	risk	N	O
for	IN	for	for	for	N	O
developing	VBG	developing	developing	develop	N	O
anaphylaxis	NN	anaphylaxis	anaphylaxis	anaphylaxi	Y	O
and	CC	and	and	and	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	O
reactions	NNS	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
these	DT	these	these	these	N	O
patients	NNS	patients	patient	patient	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
monitored	VBN	monitored	monitored	monitor	N	O
more	RBR	more	more	more	N	O
closely	RB	closely	closely	close	N	O
during	IN	during	during	dure	N	O
administration	NN	administration	administration	administr	N	O
of	IN	of	of	of	N	O
alglucosidase	JJ	alglucosidase	alglucosidase	alglucosidas	N	O
alfa	NN	alfa	alfa	alfa	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
detection	NN	detection	detection	detect	N	O
of	IN	of	of	of	N	O
antibody	NN	antibody	antibody	antibodi	N	O
formation	NN	formation	formation	format	N	O
is	VBZ	is	is	is	N	O
highly	RB	highly	highly	highli	N	O
dependent	JJ	dependent	dependent	depend	N	O
on	IN	on	on	on	N	O
the	DT	the	the	the	N	O
sensitivity	NN	sensitivity	sensitivity	sensit	N	O
and	CC	and	and	and	N	O
specificity	NN	specificity	specificity	specif	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
assay	NN	assay	assay	assay	N	O
.	.	.	.	.	N	O

Additionally	RB	additionally	additionally	addit	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
observed	JJ	observed	observed	observ	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
antibody	NN	antibody	antibody	antibodi	N	O
(	(	(	(	(	N	O
including	VBG	including	including	includ	N	O
neutralizing	VBG	neutralizing	neutralizing	neutral	N	O
antibody	NN	antibody	antibody	antibodi	N	O
)	)	)	)	)	N	O
positivity	NN	positivity	positivity	posit	N	O
in	IN	in	in	in	N	O
an	DT	an	an	an	N	O
assay	NN	assay	assay	assay	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
influenced	VBN	influenced	influenced	influenc	N	O
by	IN	by	by	by	N	O
several	JJ	several	several	sever	N	O
factors	NNS	factors	factor	factor	N	O
including	VBG	including	including	includ	N	O
assay	JJ	assay	assay	assay	N	O
methodology	NN	methodology	methodology	methodolog	N	O
,	,	,	,	,	N	O
sample	NN	sample	sample	sampl	N	O
handling	NN	handling	handling	handl	N	O
,	,	,	,	,	N	O
timing	NN	timing	timing	time	N	O
of	IN	of	of	of	N	O
sample	JJ	sample	sample	sampl	N	O
collection	NN	collection	collection	collect	N	O
,	,	,	,	,	N	O
concomitant	JJ	concomitant	concomitant	concomit	N	O
medications	NNS	medications	medication	medic	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
underlying	JJ	underlying	underlying	underli	N	O
disease	NN	disease	disease	diseas	N	O
.	.	.	.	.	N	O

For	IN	for	for	for	N	O
these	DT	these	these	these	N	O
reasons	NNS	reasons	reason	reason	N	O
,	,	,	,	,	N	O
comparison	NN	comparison	comparison	comparison	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
to	TO	to	to	to	N	O
alglucosidase	VB	alglucosidase	alglucosidase	alglucosidas	N	O
alfa	NN	alfa	alfa	alfa	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
to	TO	to	to	to	N	O
other	JJ	other	other	other	N	O
products	NNS	products	product	product	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
misleading	VBG	misleading	misleading	mislead	N	O
.	.	.	.	.	N	O

6.3	CD	6.3	6.3	6.3	N	O
Postmarketing	VBG	postmarketing	postmarketing	postmarket	N	O
Experience	NN	experience	experience	experi	N	O

The	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
identified	VBN	identified	identified	identifi	N	O
during	IN	during	during	dure	N	O
post	NN	post	post	post	N	O
approval	NN	approval	approval	approv	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
alglucosidase	NN	alglucosidase	alglucosidase	alglucosidas	N	O
alfa	NN	alfa	alfa	alfa	N	O
.	.	.	.	.	N	O

Because	IN	because	because	becaus	N	O
these	DT	these	these	these	N	O
reactions	NNS	reactions	reaction	reaction	N	O
are	VBP	are	are	are	N	O
reported	VBN	reported	reported	report	N	O
voluntarily	RB	voluntarily	voluntarily	voluntarili	N	O
from	IN	from	from	from	N	O
a	DT	a	a	a	N	O
population	NN	population	population	popul	N	O
of	IN	of	of	of	N	O
uncertain	JJ	uncertain	uncertain	uncertain	N	O
size	NN	size	size	size	N	O
,	,	,	,	,	N	O
it	PRP	it	it	it	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
always	RB	always	always	alway	N	O
possible	JJ	possible	possible	possibl	N	O
to	TO	to	to	to	N	O
reliably	VB	reliably	reliably	reliabl	N	O
estimate	VB	estimate	estimate	estim	N	O
their	PRP$	their	their	their	N	O
frequency	NN	frequency	frequency	frequenc	N	O
or	CC	or	or	or	N	O
establish	VB	establish	establish	establish	N	O
a	DT	a	a	a	N	O
causal	NN	causal	causal	causal	N	O
relationship	NN	relationship	relationship	relationship	N	O
to	TO	to	to	to	N	O
drug	NN	drug	drug	drug	N	O
exposure	NN	exposure	exposure	exposur	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
postmarketing	VBG	postmarketing	postmarketing	postmarket	N	O
experience	NN	experience	experience	experi	N	O
with	IN	with	with	with	N	O
alglucosidase	NN	alglucosidase	alglucosidase	alglucosidas	N	O
alfa	NN	alfa	alfa	alfa	N	O
,	,	,	,	,	N	O
serious	JJ	serious	serious	seriou	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
anaphylaxis	JJ	anaphylaxis	anaphylaxis	anaphylaxi	Y	B-AdverseReaction
[	NNP	[	[	[	N	O
seeBoxed	VBD	seeboxed	seeboxed	seebox	N	O
WarningandWarnings	NNP	warningandwarnings	warningandwarnings	warningandwarn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Acute	NNP	acute	acute	acut	N	B-AdverseReaction
cardiorespiratory	NN	cardiorespiratory	cardiorespiratory	cardiorespiratori	N	I-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
,	,	,	,	,	N	O
possibly	RB	possibly	possibly	possibl	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
fluid	NN	fluid	fluid	fluid	N	B-AdverseReaction
overload	NN	overload	overload	overload	N	I-AdverseReaction
,	,	,	,	,	N	O
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
infantile	JJ	infantile	infantile	infantil	N	O
-	:	-	-	-	N	O
onset	NN	onset	onset	onset	N	O
Pompe	NNP	pompe	pompe	pomp	N	O
disease	NN	disease	disease	diseas	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
pre	JJ	pre	pre	pre	N	O
-	:	-	-	-	N	O
existing	VBG	existing	existing	exist	N	O
hypertrophic	JJ	hypertrophic	hypertrophic	hypertroph	N	O
cardiomyopathy	JJ	cardiomyopathy	cardiomyopathy	cardiomyopathi	Y	O
[	NN	[	[	[	N	O
seeBoxed	VBD	seeboxed	seeboxed	seebox	N	O
WarningandWarning	NNP	warningandwarning	warningandwarning	warningandwarn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Recurrent	JJ	recurrent	recurrent	recurr	N	O
reactions	NNS	reactions	reaction	reaction	N	O
consisting	VBG	consisting	consisting	consist	N	O
of	IN	of	of	of	N	O
flu	JJ	flu	flu	flu	Y	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
like	IN	like	like	like	N	I-AdverseReaction
illness	NN	illness	illness	ill	N	I-AdverseReaction
or	CC	or	or	or	N	O
a	DT	a	a	a	N	O
combination	NN	combination	combination	combin	N	O
of	IN	of	of	of	N	O
events	NNS	events	event	event	N	O
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
pyrexia	NN	pyrexia	pyrexia	pyrexia	Y	B-AdverseReaction
,	,	,	,	,	N	O
chills	NNS	chills	chill	chill	Y	B-AdverseReaction
,	,	,	,	,	N	O
myalgia	NN	myalgia	myalgia	myalgia	Y	B-AdverseReaction
,	,	,	,	,	N	O
arthralgia	NN	arthralgia	arthralgia	arthralgia	Y	B-AdverseReaction
,	,	,	,	,	N	O
pain	NN	pain	pain	pain	Y	B-AdverseReaction
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
fatigue	NN	fatigue	fatigue	fatigu	Y	B-AdverseReaction
occurring	NN	occurring	occurring	occur	N	O
after	IN	after	after	after	N	O
completion	NN	completion	completion	complet	N	O
of	IN	of	of	of	N	O
infusions	NNS	infusions	infusion	infus	N	O
and	CC	and	and	and	N	O
lasting	VBG	lasting	lasting	last	N	O
usually	RB	usually	usually	usual	N	O
for	IN	for	for	for	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
3	CD	3	3	3	N	O
days	NNS	days	day	day	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
observed	VBN	observed	observed	observ	N	O
in	IN	in	in	in	N	O
some	DT	some	some	some	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
alglucosidase	NN	alglucosidase	alglucosidase	alglucosidas	N	O
alfa	NN	alfa	alfa	alfa	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
majority	NN	majority	majority	major	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
were	VBD	were	were	were	N	O
able	JJ	able	able	abl	N	O
to	TO	to	to	to	N	O
be	VB	be	be	be	N	O
rechallenged	VBN	rechallenged	rechallenged	rechalleng	N	O
with	IN	with	with	with	N	O
alglucosidase	NN	alglucosidase	alglucosidase	alglucosidas	N	O
alfa	NN	alfa	alfa	alfa	N	O
using	VBG	using	using	use	N	O
lower	JJR	lower	lower	lower	N	O
doses	NNS	doses	dos	dose	N	O
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
pretreatment	NN	pretreatment	pretreatment	pretreat	N	O
with	IN	with	with	with	N	O
anti	JJ	anti	anti	anti	N	O
-	:	-	-	-	N	O
inflammatory	NN	inflammatory	inflammatory	inflammatori	N	O
drugs	NNS	drugs	drug	drug	N	O
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
corticosteroids	NNS	corticosteroids	corticosteroid	corticosteroid	N	O
and	CC	and	and	and	N	O
were	VBD	were	were	were	N	O
able	JJ	able	able	abl	N	O
to	TO	to	to	to	N	O
continue	VB	continue	continue	continu	N	O
treatment	NN	treatment	treatment	treatment	N	O
under	IN	under	under	under	N	O
close	JJ	close	close	close	N	O
clinical	JJ	clinical	clinical	clinic	N	O
supervision	NN	supervision	supervision	supervis	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
addition	NN	addition	addition	addit	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
[	VBP	[	[	[	N	O
seeAdverse	JJ	seeadverse	seeadverse	seeadvers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)]	NN	)]	)]	)]	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
2	CD	2	2	2	N	O
patients	NNS	patients	patient	patient	N	O
and	CC	and	and	and	N	O
included	VBD	included	included	includ	N	O
:	:	:	:	:	N	O
anaphylactic	JJ	anaphylactic	anaphylactic	anaphylact	N	B-AdverseReaction
shock	NN	shock	shock	shock	Y	I-AdverseReaction
,	,	,	,	,	N	O
respiratory	JJ	respiratory	respiratory	respiratori	N	B-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
,	,	,	,	,	N	O
respiratory	NN	respiratory	respiratory	respiratori	N	B-AdverseReaction
arrest	NN	arrest	arrest	arrest	N	I-AdverseReaction
,	,	,	,	,	N	O
cardiac	JJ	cardiac	cardiac	cardiac	N	B-AdverseReaction
arrest	NN	arrest	arrest	arrest	N	I-AdverseReaction
,	,	,	,	,	N	O
hypoxia	NN	hypoxia	hypoxia	hypoxia	Y	B-AdverseReaction
,	,	,	,	,	N	O
dyspnea	NN	dyspnea	dyspnea	dyspnea	Y	B-AdverseReaction
,	,	,	,	,	N	O
wheezing	VBG	wheezing	wheezing	wheez	Y	B-AdverseReaction
,	,	,	,	,	N	O
convulsions	NNS	convulsions	convulsion	convuls	Y	B-AdverseReaction
,	,	,	,	,	N	O
peripheral	JJ	peripheral	peripheral	peripher	N	B-AdverseReaction
coldness	NN	coldness	coldness	cold	Y	I-AdverseReaction
,	,	,	,	,	N	O
restlessness	NN	restlessness	restlessness	restless	Y	B-AdverseReaction
,	,	,	,	,	N	O
nervousness	NN	nervousness	nervousness	nervous	Y	B-AdverseReaction
,	,	,	,	,	N	O
back	RB	back	back	back	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
stridor	NN	stridor	stridor	stridor	Y	B-AdverseReaction
,	,	,	,	,	N	O
pharyngeal	NN	pharyngeal	pharyngeal	pharyng	N	B-AdverseReaction
edema	NN	edema	edema	edema	Y	I-AdverseReaction
,	,	,	,	,	N	O
abdominal	JJ	abdominal	abdominal	abdomin	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
apnea	NN	apnea	apnea	apnea	Y	B-AdverseReaction
,	,	,	,	,	N	O
muscle	NN	muscle	muscle	muscl	N	B-AdverseReaction
spasm	NN	spasm	spasm	spasm	N	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
conjunctivitis	NN	conjunctivitis	conjunctivitis	conjunct	Y	B-AdverseReaction
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
addition	NN	addition	addition	addit	N	O
,	,	,	,	,	N	O
one	CD	one	one	one	N	O
case	NN	case	case	case	N	O
of	IN	of	of	of	N	O
hyperparathyroidism	NN	hyperparathyroidism	hyperparathyroidism	hyperparathyroid	Y	B-AdverseReaction
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
.	.	.	.	.	N	O

Systemic	NNP	systemic	systemic	system	N	B-AdverseReaction
and	CC	and	and	and	N	O
cutaneous	JJ	cutaneous	cutaneous	cutan	N	B-AdverseReaction
immune	JJ	immune	immune	immun	N	I-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
mediated	JJ	mediated	mediated	mediat	N	I-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
proteinuria	NNS	proteinuria	proteinuria	proteinuria	Y	B-AdverseReaction
and	CC	and	and	and	N	O
nephrotic	JJ	nephrotic	nephrotic	nephrot	N	B-AdverseReaction
syndrome	NN	syndrome	syndrome	syndrom	N	I-AdverseReaction
secondary	JJ	secondary	secondary	secondari	N	O
to	TO	to	to	to	N	O
membranous	JJ	membranous	membranous	membran	N	B-AdverseReaction
glomerulonephritis	NN	glomerulonephritis	glomerulonephritis	glomerulonephr	Y	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
necrotizing	VBG	necrotizing	necrotizing	necrot	N	B-AdverseReaction
skin	JJ	skin	skin	skin	N	I-AdverseReaction
lesions	NNS	lesions	lesion	lesion	N	I-AdverseReaction
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
postmarketing	VBG	postmarketing	postmarketing	postmarket	N	O
safety	NN	safety	safety	safeti	N	O
experience	NN	experience	experience	experi	N	O
with	IN	with	with	with	N	O
alglucosidase	NN	alglucosidase	alglucosidase	alglucosidas	N	O
alfa	NN	alfa	alfa	alfa	N	O
[	NNP	[	[	[	N	O
seeWarnings	NNS	seewarnings	seewarnings	seewarn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O
\n\n	VB	\n\n	\n\n	\n\n	N	O
BOXED	NNP	boxed	boxed	box	N	O
WARNING	NNP	warning	warning	warn	N	O
:	:	:	:	:	N	O
WARNING	NN	warning	warning	warn	N	O
:	:	:	:	:	N	O
RISK	NN	risk	risk	risk	N	B-Factor
OF	IN	of	of	of	N	O
ANAPHYLAXIS	NNP	anaphylaxis	anaphylaxis	anaphylaxi	Y	B-AdverseReaction
,	,	,	,	,	N	O
HYPERSENSITIVITY	NNP	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
AND	NNP	and	and	and	N	O
IMMUNE	NNP	immune	immune	immun	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
MEDIATED	NNP	mediated	mediated	mediat	N	I-AdverseReaction
REACTIONS	NNP	reactions	reaction	reaction	N	I-AdverseReaction
,	,	,	,	,	N	O
AND	NNP	and	and	and	N	O
RISK	NNP	risk	risk	risk	N	B-Factor
OF	NNP	of	of	of	N	O
CARDIORESPIRATORY	NNP	cardiorespiratory	cardiorespiratory	cardiorespiratori	N	B-AdverseReaction
FAILURE	NNP	failure	failure	failur	N	I-AdverseReaction
\n\n	VBZ	\n\n	\n\n	\n\n	N	O
WARNING	NN	warning	warning	warn	N	O
:	:	:	:	:	N	O
RISK	NN	risk	risk	risk	N	B-Factor
OF	IN	of	of	of	N	O
ANAPHYLAXIS	NNP	anaphylaxis	anaphylaxis	anaphylaxi	Y	B-AdverseReaction
,	,	,	,	,	N	O
HYPERSENSITIVITY	NNP	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
AND	NNP	and	and	and	N	O
IMMUNE	NNP	immune	immune	immun	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
MEDIATED	NNP	mediated	mediated	mediat	N	I-AdverseReaction
REACTIONS	NNP	reactions	reaction	reaction	N	I-AdverseReaction
,	,	,	,	,	N	O
AND	NNP	and	and	and	N	O
RISK	NNP	risk	risk	risk	N	B-Factor
OF	NNP	of	of	of	N	O
CARDIORESPIRATORY	NNP	cardiorespiratory	cardiorespiratory	cardiorespiratori	N	B-AdverseReaction
FAILURE	NNP	failure	failure	failur	N	I-AdverseReaction
\n\n	NNP	\n\n	\n\n	\n\n	N	O
Life	NNP	life	life	life	N	B-Severity
-	:	-	-	-	N	I-Severity
threatening	VBG	threatening	threatening	threaten	N	I-Severity
anaphylactic	JJ	anaphylactic	anaphylactic	anaphylact	N	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
and	CC	and	and	and	N	O
severe	JJ	severe	severe	sever	N	B-Severity
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
,	,	,	,	,	N	O
presenting	VBG	presenting	presenting	present	N	O
as	IN	as	a	as	N	O
respiratory	NN	respiratory	respiratory	respiratori	N	B-AdverseReaction
distress	NN	distress	distress	distress	N	I-AdverseReaction
,	,	,	,	,	N	O
hypoxia	NN	hypoxia	hypoxia	hypoxia	Y	B-AdverseReaction
,	,	,	,	,	N	O
apnea	NN	apnea	apnea	apnea	Y	B-AdverseReaction
,	,	,	,	,	N	O
dyspnea	NN	dyspnea	dyspnea	dyspnea	Y	B-AdverseReaction
,	,	,	,	,	N	O
bradycardia	NN	bradycardia	bradycardia	bradycardia	Y	B-AdverseReaction
,	,	,	,	,	N	O
tachycardia	NN	tachycardia	tachycardia	tachycardia	Y	B-AdverseReaction
,	,	,	,	,	N	O
bronchospasm	NN	bronchospasm	bronchospasm	bronchospasm	Y	B-AdverseReaction
,	,	,	,	,	N	O
throat	NN	throat	throat	throat	N	B-AdverseReaction
tightness	NN	tightness	tightness	tight	N	I-AdverseReaction
,	,	,	,	,	N	O
hypotension	NN	hypotension	hypotension	hypotens	Y	B-AdverseReaction
,	,	,	,	,	N	O
angioedema	NN	angioedema	angioedema	angioedema	Y	B-AdverseReaction
(	(	(	(	(	N	O
including	VBG	including	including	includ	N	O
tongue	NN	tongue	tongue	tongu	N	B-AdverseReaction
or	CC	or	or	or	N	O
lip	NN	lip	lip	lip	N	B-AdverseReaction
swelling	NN	swelling	swelling	swell	Y	I-AdverseReaction
,	,	,	,	,	N	O
periorbital	JJ	periorbital	periorbital	periorbit	N	B-AdverseReaction
edema	NN	edema	edema	edema	Y	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
face	NN	face	face	face	N	B-AdverseReaction
edema	NN	edema	edema	edema	Y	I-AdverseReaction
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
urticaria	RB	urticaria	urticaria	urticaria	Y	B-AdverseReaction
,	,	,	,	,	N	O
have	VBP	have	have	have	N	O
occurred	VBN	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
some	DT	some	some	some	N	O
patients	NNS	patients	patient	patient	N	O
during	IN	during	during	dure	N	O
and	CC	and	and	and	N	O
after	IN	after	after	after	N	O
alglucosidase	JJ	alglucosidase	alglucosidase	alglucosidas	N	O
alfa	JJ	alfa	alfa	alfa	N	O
infusions	NNS	infusions	infusion	infus	N	O
.	.	.	.	.	N	O

Immune	NNP	immune	immune	immun	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
mediated	VBD	mediated	mediated	mediat	N	I-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
presenting	VBG	presenting	presenting	present	N	O
as	IN	as	a	as	N	O
proteinuria	NN	proteinuria	proteinuria	proteinuria	Y	B-AdverseReaction
,	,	,	,	,	N	O
nephrotic	JJ	nephrotic	nephrotic	nephrot	N	B-AdverseReaction
syndrome	NN	syndrome	syndrome	syndrom	N	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
necrotizing	VBG	necrotizing	necrotizing	necrot	N	B-AdverseReaction
skin	JJ	skin	skin	skin	N	I-AdverseReaction
lesions	NNS	lesions	lesion	lesion	N	I-AdverseReaction
have	VBP	have	have	have	N	O
occurred	VBN	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
some	DT	some	some	some	N	O
patients	NNS	patients	patient	patient	N	O
following	VBG	following	following	follow	N	O
alglucosidase	JJ	alglucosidase	alglucosidase	alglucosidas	N	O
alfa	JJ	alfa	alfa	alfa	N	O
treatment	NN	treatment	treatment	treatment	N	O
.	.	.	.	.	N	O

Closely	RB	closely	closely	close	N	O
observe	JJ	observe	observe	observ	N	O
patients	NNS	patients	patient	patient	N	O
during	IN	during	during	dure	N	O
and	CC	and	and	and	N	O
after	IN	after	after	after	N	O
alglucosidase	NN	alglucosidase	alglucosidase	alglucosidas	N	O
alfa	JJ	alfa	alfa	alfa	N	O
administration	NN	administration	administration	administr	N	O
and	CC	and	and	and	N	O
be	VB	be	be	be	N	O
prepared	VBN	prepared	prepared	prepar	N	O
to	TO	to	to	to	N	O
manage	VB	manage	manage	manag	N	O
anaphylaxis	NN	anaphylaxis	anaphylaxis	anaphylaxi	Y	O
and	CC	and	and	and	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	O
reactions	NNS	reactions	reaction	reaction	N	O
.	.	.	.	.	N	O

Inform	NNP	inform	inform	inform	N	O
patients	NNS	patients	patient	patient	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
signs	NNS	signs	sign	sign	N	O
and	CC	and	and	and	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
anaphylaxis	NN	anaphylaxis	anaphylaxis	anaphylaxi	Y	O
,	,	,	,	,	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	O
reactions	NNS	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
immune	JJ	immune	immune	immun	N	O
-	:	-	-	-	N	O
mediated	VBN	mediated	mediated	mediat	N	O
reactions	NNS	reactions	reaction	reaction	N	O
and	CC	and	and	and	N	O
have	VBP	have	have	have	N	O
them	PRP	them	them	them	N	O
seek	VB	seek	seek	seek	N	O
immediate	JJ	immediate	immediate	immedi	N	O
medical	JJ	medical	medical	medic	N	O
care	NN	care	care	care	N	O
should	MD	should	should	should	N	O
signs	NNS	signs	sign	sign	N	O
and	CC	and	and	and	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
occur	VBP	occur	occur	occur	N	O
[	JJ	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNS	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
,	,	,	,	,	N	O
5.2	CD	5.2	5.2	5.2	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Infantile	NNP	infantile	infantile	infantil	N	O
-	:	-	-	-	N	O
onset	NN	onset	onset	onset	N	O
Pompe	NNP	pompe	pompe	pomp	N	O
disease	NN	disease	disease	diseas	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
compromised	JJ	compromised	compromised	compromis	N	O
cardiac	NN	cardiac	cardiac	cardiac	N	O
or	CC	or	or	or	N	O
respiratory	JJ	respiratory	respiratory	respiratori	N	O
function	NN	function	function	function	N	O
may	MD	may	may	may	N	B-Factor
be	VB	be	be	be	N	O
at	IN	at	at	at	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
serious	JJ	serious	serious	seriou	N	B-Severity
acute	JJ	acute	acute	acut	N	B-AdverseReaction
exacerbation	NN	exacerbation	exacerbation	exacerb	N	I-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
their	PRP$	their	their	their	N	O
cardiac	NN	cardiac	cardiac	cardiac	N	I-AdverseReaction
or	CC	or	or	or	N	O
respiratory	NN	respiratory	respiratory	respiratori	N	I-AdverseReaction
compromise	NN	compromise	compromise	compromis	N	I-AdverseReaction
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
fluid	VB	fluid	fluid	fluid	N	B-AdverseReaction
overload	NN	overload	overload	overload	N	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
require	VBP	require	require	requir	N	O
additional	JJ	additional	additional	addit	N	O
monitoring	NN	monitoring	monitoring	monitor	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

WARNING	NN	warning	warning	warn	N	O
:	:	:	:	:	N	O
RISK	NN	risk	risk	risk	N	B-Factor
OF	IN	of	of	of	N	O
ANAPHYLAXIS	NNP	anaphylaxis	anaphylaxis	anaphylaxi	Y	B-AdverseReaction
,	,	,	,	,	N	O
HYPERSENSITIVITY	NNP	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
AND	NNP	and	and	and	N	O
IMMUNE	NNP	immune	immune	immun	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
MEDIATED	NNP	mediated	mediated	mediat	N	I-AdverseReaction
REACTIONS	NNP	reactions	reaction	reaction	N	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
RISK	NNP	risk	risk	risk	N	B-Factor
OF	NNP	of	of	of	N	O
CARDIORESPIRATORY	NNP	cardiorespiratory	cardiorespiratory	cardiorespiratori	N	B-AdverseReaction
FAILURE	NNP	failure	failure	failur	N	I-AdverseReaction
\n\n\n\n	NNP	\n\n\n\n	\n\n\n\n	\n\n\n\n	N	O
See	NNP	see	see	see	N	O
full	JJ	full	full	full	N	O
prescribing	VBG	prescribing	prescribing	prescrib	N	O
information	NN	information	information	inform	N	O
for	IN	for	for	for	N	O
complete	JJ	complete	complete	complet	N	O
boxed	JJ	boxed	boxed	box	N	O
warning	NN	warning	warning	warn	N	O
.	.	.	.	.	N	O

Life	NNP	life	life	life	N	B-Severity
-	:	-	-	-	N	I-Severity
threatening	VBG	threatening	threatening	threaten	N	I-Severity
anaphylactic	JJ	anaphylactic	anaphylactic	anaphylact	N	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
and	CC	and	and	and	N	O
severe	JJ	severe	severe	sever	N	B-Severity
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
have	VBP	have	have	have	N	O
occurred	VBN	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
some	DT	some	some	some	N	O
patients	NNS	patients	patient	patient	N	O
during	IN	during	during	dure	N	O
and	CC	and	and	and	N	O
after	IN	after	after	after	N	O
alglucosidase	JJ	alglucosidase	alglucosidase	alglucosidas	N	O
alfa	JJ	alfa	alfa	alfa	N	O
infusions	NNS	infusions	infusion	infus	N	O
.	.	.	.	.	N	O

Immune	NNP	immune	immune	immun	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
mediated	VBD	mediated	mediated	mediat	N	I-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
presenting	VBG	presenting	presenting	present	N	O
as	IN	as	a	as	N	O
proteinuria	NN	proteinuria	proteinuria	proteinuria	Y	B-AdverseReaction
,	,	,	,	,	N	O
nephrotic	JJ	nephrotic	nephrotic	nephrot	N	B-AdverseReaction
syndrome	NN	syndrome	syndrome	syndrom	N	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
necrotizing	VBG	necrotizing	necrotizing	necrot	N	B-AdverseReaction
skin	JJ	skin	skin	skin	N	I-AdverseReaction
lesions	NNS	lesions	lesion	lesion	N	I-AdverseReaction
have	VBP	have	have	have	N	O
occurred	VBN	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
some	DT	some	some	some	N	O
patients	NNS	patients	patient	patient	N	O
following	VBG	following	following	follow	N	O
alglucosidase	JJ	alglucosidase	alglucosidase	alglucosidas	N	O
alfa	JJ	alfa	alfa	alfa	N	O
treatment	NN	treatment	treatment	treatment	N	O
.	.	.	.	.	N	O

Closely	RB	closely	closely	close	N	O
observe	JJ	observe	observe	observ	N	O
patients	NNS	patients	patient	patient	N	O
during	IN	during	during	dure	N	O
and	CC	and	and	and	N	O
after	IN	after	after	after	N	O
alglucosidase	NN	alglucosidase	alglucosidase	alglucosidas	N	O
alfa	JJ	alfa	alfa	alfa	N	O
administration	NN	administration	administration	administr	N	O
and	CC	and	and	and	N	O
be	VB	be	be	be	N	O
prepared	VBN	prepared	prepared	prepar	N	O
to	TO	to	to	to	N	O
manage	VB	manage	manage	manag	N	O
anaphylaxis	NN	anaphylaxis	anaphylaxis	anaphylaxi	Y	O
and	CC	and	and	and	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	O
reactions	NNS	reactions	reaction	reaction	N	O
.	.	.	.	.	N	O

Inform	NNP	inform	inform	inform	N	O
patients	NNS	patients	patient	patient	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
signs	NNS	signs	sign	sign	N	O
and	CC	and	and	and	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
anaphylaxis	NN	anaphylaxis	anaphylaxis	anaphylaxi	Y	O
,	,	,	,	,	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	O
reactions	NNS	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
immune	JJ	immune	immune	immun	N	O
-	:	-	-	-	N	O
mediated	VBN	mediated	mediated	mediat	N	O
reactions	NNS	reactions	reaction	reaction	N	O
and	CC	and	and	and	N	O
have	VBP	have	have	have	N	O
them	PRP	them	them	them	N	O
seek	VB	seek	seek	seek	N	O
immediate	JJ	immediate	immediate	immedi	N	O
medical	JJ	medical	medical	medic	N	O
care	NN	care	care	care	N	O
should	MD	should	should	should	N	O
signs	NNS	signs	sign	sign	N	O
and	CC	and	and	and	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
occur	VBP	occur	occur	occur	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
,	,	,	,	,	N	O
5.2	CD	5.2	5.2	5.2	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Infantile	NNP	infantile	infantile	infantil	N	O
-	:	-	-	-	N	O
onset	NN	onset	onset	onset	N	O
Pompe	NNP	pompe	pompe	pomp	N	O
disease	NN	disease	disease	diseas	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
compromised	JJ	compromised	compromised	compromis	N	O
cardiac	NN	cardiac	cardiac	cardiac	N	O
or	CC	or	or	or	N	O
respiratory	JJ	respiratory	respiratory	respiratori	N	O
function	NN	function	function	function	N	O
may	MD	may	may	may	N	B-Factor
be	VB	be	be	be	N	O
at	IN	at	at	at	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
serious	JJ	serious	serious	seriou	N	B-Severity
acute	JJ	acute	acute	acut	N	B-AdverseReaction
exacerbation	NN	exacerbation	exacerbation	exacerb	N	I-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
their	PRP$	their	their	their	N	O
cardiac	NN	cardiac	cardiac	cardiac	N	I-AdverseReaction
or	CC	or	or	or	N	O
respiratory	NN	respiratory	respiratory	respiratori	N	I-AdverseReaction
compromise	NN	compromise	compromise	compromis	N	I-AdverseReaction
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
fluid	VB	fluid	fluid	fluid	N	B-AdverseReaction
overload	NN	overload	overload	overload	N	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
require	VBP	require	require	requir	N	O
additional	JJ	additional	additional	addit	N	O
monitoring	NN	monitoring	monitoring	monitor	N	O
(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O
\n	$	\n	\n	\n	N	O
5	CD	5	5	5	N	O
WARNINGS	NNP	warnings	warning	warn	N	O
AND	NNP	and	and	and	N	O
PRECAUTIONS	NNP	precautions	precaution	precaut	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
Anaphylaxis	NNP	anaphylaxis	anaphylaxis	anaphylaxi	Y	B-AdverseReaction
and	CC	and	and	and	N	O
Hypersensitivity	NNP	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
Reactions	NNP	reactions	reaction	reaction	N	I-AdverseReaction
:	:	:	:	:	N	O
Life	NNP	life	life	life	N	B-Severity
-	:	-	-	-	N	I-Severity
threatening	VBG	threatening	threatening	threaten	N	I-Severity
anaphylaxis	NN	anaphylaxis	anaphylaxis	anaphylaxi	Y	B-AdverseReaction
and	CC	and	and	and	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
observed	VBN	observed	observed	observ	N	O
in	IN	in	in	in	N	O
some	DT	some	some	some	N	O
patients	NNS	patients	patient	patient	N	O
during	IN	during	during	dure	N	O
and	CC	and	and	and	N	O
after	IN	after	after	after	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
alglucosidase	NN	alglucosidase	alglucosidase	alglucosidas	N	O
alfa	NN	alfa	alfa	alfa	N	O
.	.	.	.	.	N	O

Ensure	NN	ensure	ensure	ensur	N	O
that	WDT	that	that	that	N	O
appropriate	VBP	appropriate	appropriate	appropri	N	O
medical	JJ	medical	medical	medic	N	O
support	NN	support	support	support	N	O
measures	NNS	measures	measure	measur	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
cardiopulmonary	JJ	cardiopulmonary	cardiopulmonary	cardiopulmonari	N	O
resuscitation	NN	resuscitation	resuscitation	resuscit	Y	O
equipment	NN	equipment	equipment	equip	N	O
,	,	,	,	,	N	O
are	VBP	are	are	are	N	O
readily	RB	readily	readily	readili	N	O
available	JJ	available	available	avail	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
anaphylaxis	NNS	anaphylaxis	anaphylaxis	anaphylaxi	Y	O
or	CC	or	or	or	N	O
severe	JJ	severe	severe	sever	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	O
reactions	NNS	reactions	reaction	reaction	N	O
occur	VBP	occur	occur	occur	N	O
,	,	,	,	,	N	O
immediately	RB	immediately	immediately	immedi	N	O
discontinue	JJ	discontinue	discontinue	discontinu	N	O
infusion	NN	infusion	infusion	infus	Y	O
and	CC	and	and	and	N	O
initiate	VB	initiate	initiate	initi	N	O
appropriate	JJ	appropriate	appropriate	appropri	N	O
medical	JJ	medical	medical	medic	N	O
treatment	NN	treatment	treatment	treatment	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Immune	NNP	immune	immune	immun	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
Mediated	VBD	mediated	mediated	mediat	N	I-AdverseReaction
Reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
:	:	:	:	:	N	O
Monitor	NN	monitor	monitor	monitor	N	O
patients	NNS	patients	patient	patient	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
development	NN	development	development	develop	N	O
of	IN	of	of	of	N	O
systemic	JJ	systemic	systemic	system	N	O
immune	JJ	immune	immune	immun	N	O
-	:	-	-	-	N	O
mediated	VBN	mediated	mediated	mediat	N	O
reactions	NNS	reactions	reaction	reaction	N	O
involving	VBG	involving	involving	involv	N	O
skin	NN	skin	skin	skin	N	O
and	CC	and	and	and	N	O
other	JJ	other	other	other	N	O
organs	NNS	organs	organ	organ	N	O
(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Risk	NN	risk	risk	risk	N	B-Factor
of	IN	of	of	of	N	O
Acute	NNP	acute	acute	acut	N	B-AdverseReaction
Cardiorespiratory	NNP	cardiorespiratory	cardiorespiratory	cardiorespiratori	N	I-AdverseReaction
Failure	NN	failure	failure	failur	N	I-AdverseReaction
:	:	:	:	:	N	O
Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
compromised	JJ	compromised	compromised	compromis	N	O
cardiac	NN	cardiac	cardiac	cardiac	N	O
or	CC	or	or	or	N	O
respiratory	JJ	respiratory	respiratory	respiratori	N	O
function	NN	function	function	function	N	O
may	MD	may	may	may	N	B-Factor
be	VB	be	be	be	N	O
at	IN	at	at	at	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
acute	JJ	acute	acute	acut	N	B-AdverseReaction
cardiorespiratory	JJ	cardiorespiratory	cardiorespiratory	cardiorespiratori	N	I-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
.	.	.	.	.	N	O

Caution	NN	caution	caution	caution	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
exercised	VBN	exercised	exercised	exercis	N	O
when	WRB	when	when	when	N	O
administering	VBG	administering	administering	administ	N	O
alglucosidase	NN	alglucosidase	alglucosidase	alglucosidas	N	O
alfa	NN	alfa	alfa	alfa	N	O
to	TO	to	to	to	N	O
patients	NNS	patients	patient	patient	N	O
susceptible	JJ	susceptible	susceptible	suscept	N	O
to	TO	to	to	to	N	O
fluid	VB	fluid	fluid	fluid	N	O
volume	NN	volume	volume	volum	N	O
overload	NN	overload	overload	overload	N	O
.	.	.	.	.	N	O

Appropriate	NNP	appropriate	appropriate	appropri	N	O
medical	JJ	medical	medical	medic	N	O
support	NN	support	support	support	N	O
and	CC	and	and	and	N	O
monitoring	NN	monitoring	monitoring	monitor	N	O
measures	NNS	measures	measure	measur	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
available	JJ	available	available	avail	N	O
during	IN	during	during	dure	N	O
infusion	NN	infusion	infusion	infus	Y	O
(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Risk	NN	risk	risk	risk	N	B-Factor
of	IN	of	of	of	N	O
Cardiac	NNP	cardiac	cardiac	cardiac	N	B-AdverseReaction
Arrhythmia	NNP	arrhythmia	arrhythmia	arrhythmia	Y	I-AdverseReaction
and	CC	and	and	and	N	O
Sudden	NNP	sudden	sudden	sudden	N	B-AdverseReaction
Cardiac	NNP	cardiac	cardiac	cardiac	N	I-AdverseReaction
Death	NNP	death	death	death	Y	I-AdverseReaction
during	IN	during	during	dure	N	O
General	NNP	general	general	gener	N	O
Anesthesia	NNP	anesthesia	anesthesia	anesthesia	Y	O
for	IN	for	for	for	N	O
Central	NNP	central	central	central	N	O
Venous	NNP	venous	venous	venou	N	O
Catheter	NNP	catheter	catheter	cathet	N	O
Placement	NN	placement	placement	placement	N	O
:	:	:	:	:	N	O
Caution	NN	caution	caution	caution	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
used	VBN	used	used	use	N	O
when	WRB	when	when	when	N	O
administering	VBG	administering	administering	administ	N	O
general	JJ	general	general	gener	N	O
anesthesia	NN	anesthesia	anesthesia	anesthesia	Y	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
placement	NN	placement	placement	placement	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
central	JJ	central	central	central	N	O
venous	JJ	venous	venous	venou	N	O
catheter	NN	catheter	catheter	cathet	N	O
intended	VBN	intended	intended	intend	N	O
for	IN	for	for	for	N	O
alglucosidase	NN	alglucosidase	alglucosidase	alglucosidas	N	O
alfa	NN	alfa	alfa	alfa	N	O
infusion	NN	infusion	infusion	infus	Y	O
(	(	(	(	(	N	O
5.4	CD	5.4	5.4	5.4	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

5.1	CD	5.1	5.1	5.1	N	O

Anaphylaxis	NNP	anaphylaxis	anaphylaxis	anaphylaxi	Y	O
and	CC	and	and	and	N	O
Hypersensitivity	NNP	hypersensitivity	hypersensitivity	hypersensit	Y	O
Reactions	NNP	reactions	reaction	reaction	N	O

Anaphylaxis	NNP	anaphylaxis	anaphylaxis	anaphylaxi	Y	B-AdverseReaction
and	CC	and	and	and	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
observed	VBN	observed	observed	observ	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
during	IN	during	during	dure	N	O
and	CC	and	and	and	N	O
up	RB	up	up	up	N	O
to	TO	to	to	to	N	O
3	CD	3	3	3	N	O
hours	NNS	hours	hour	hour	N	O
after	IN	after	after	after	N	O
alglucosidase	NN	alglucosidase	alglucosidase	alglucosidas	N	O
alfa	JJ	alfa	alfa	alfa	N	O
infusion	NN	infusion	infusion	infus	Y	O
.	.	.	.	.	N	O

Some	DT	some	some	some	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
reactions	NNS	reactions	reaction	reaction	N	O
were	VBD	were	were	were	N	O
life	NN	life	life	life	N	B-Severity
-	:	-	-	-	N	I-Severity
threatening	NN	threatening	threatening	threaten	N	I-Severity
and	CC	and	and	and	N	O
included	VBD	included	included	includ	N	O
anaphylactic	JJ	anaphylactic	anaphylactic	anaphylact	N	B-AdverseReaction
shock	NN	shock	shock	shock	Y	I-AdverseReaction
,	,	,	,	,	N	O
cardiac	JJ	cardiac	cardiac	cardiac	N	B-AdverseReaction
arrest	NN	arrest	arrest	arrest	N	I-AdverseReaction
,	,	,	,	,	N	O
respiratory	NN	respiratory	respiratory	respiratori	N	B-AdverseReaction
arrest	NN	arrest	arrest	arrest	N	I-AdverseReaction
,	,	,	,	,	N	O
respiratory	NN	respiratory	respiratory	respiratori	N	B-AdverseReaction
distress	NN	distress	distress	distress	N	I-AdverseReaction
,	,	,	,	,	N	O
hypoxia	NN	hypoxia	hypoxia	hypoxia	Y	B-AdverseReaction
,	,	,	,	,	N	O
apnea	NN	apnea	apnea	apnea	Y	B-AdverseReaction
,	,	,	,	,	N	O
dyspnea	NN	dyspnea	dyspnea	dyspnea	Y	B-AdverseReaction
,	,	,	,	,	N	O
bradycardia	NN	bradycardia	bradycardia	bradycardia	Y	B-AdverseReaction
,	,	,	,	,	N	O
tachycardia	NN	tachycardia	tachycardia	tachycardia	Y	B-AdverseReaction
,	,	,	,	,	N	O
bronchospasm	NN	bronchospasm	bronchospasm	bronchospasm	Y	B-AdverseReaction
,	,	,	,	,	N	O
throat	NN	throat	throat	throat	N	B-AdverseReaction
tightness	NN	tightness	tightness	tight	N	I-AdverseReaction
,	,	,	,	,	N	O
hypotension	NN	hypotension	hypotension	hypotens	Y	B-AdverseReaction
,	,	,	,	,	N	O
angioedema	NN	angioedema	angioedema	angioedema	Y	B-AdverseReaction
(	(	(	(	(	N	O
including	VBG	including	including	includ	N	O
tongue	NN	tongue	tongue	tongu	N	B-AdverseReaction
or	CC	or	or	or	N	O
lip	NN	lip	lip	lip	N	B-AdverseReaction
swelling	NN	swelling	swelling	swell	Y	I-AdverseReaction
,	,	,	,	,	N	O
periorbital	JJ	periorbital	periorbital	periorbit	N	B-AdverseReaction
edema	NN	edema	edema	edema	Y	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
face	NN	face	face	face	N	B-AdverseReaction
edema	NN	edema	edema	edema	Y	I-AdverseReaction
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
urticaria	NNS	urticaria	urticaria	urticaria	Y	B-AdverseReaction
.	.	.	.	.	N	O

Other	JJ	other	other	other	N	O
accompanying	VBG	accompanying	accompanying	accompani	N	O
reactions	NNS	reactions	reaction	reaction	N	O
included	VBD	included	included	includ	N	O
chest	JJS	chest	chest	chest	N	B-AdverseReaction
discomfort	NN	discomfort	discomfort	discomfort	Y	I-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
wheezing	NN	wheezing	wheezing	wheez	Y	B-AdverseReaction
,	,	,	,	,	N	O
tachypnea	NN	tachypnea	tachypnea	tachypnea	Y	B-AdverseReaction
,	,	,	,	,	N	O
cyanosis	NN	cyanosis	cyanosis	cyanosi	Y	B-AdverseReaction
,	,	,	,	,	N	O
decreased	VBD	decreased	decreased	decreas	N	B-AdverseReaction
oxygen	NN	oxygen	oxygen	oxygen	N	I-AdverseReaction
saturation	NN	saturation	saturation	satur	N	I-AdverseReaction
,	,	,	,	,	N	O
convulsions	NNS	convulsions	convulsion	convuls	Y	B-AdverseReaction
,	,	,	,	,	N	O
pruritus	NN	pruritus	pruritus	pruritu	Y	B-AdverseReaction
,	,	,	,	,	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction
,	,	,	,	,	N	O
hyperhidrosis	NN	hyperhidrosis	hyperhidrosis	hyperhidrosi	Y	B-AdverseReaction
,	,	,	,	,	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
,	,	,	,	,	N	O
dizziness	NN	dizziness	dizziness	dizzi	Y	B-AdverseReaction
,	,	,	,	,	N	O
hypertension	NN	hypertension	hypertension	hypertens	Y	B-AdverseReaction
increased	VBD	increased	increased	increas	N	B-AdverseReaction
blood	NN	blood	blood	blood	N	I-AdverseReaction
pressure	NN	pressure	pressure	pressur	N	I-AdverseReaction
,	,	,	,	,	N	O
flushing	VBG	flushing	flushing	flush	Y	B-AdverseReaction
feeling	VBG	feeling	feeling	feel	N	B-AdverseReaction
hot	JJ	hot	hot	hot	N	I-AdverseReaction
,	,	,	,	,	N	O
erythema	JJ	erythema	erythema	erythema	Y	B-AdverseReaction
,	,	,	,	,	N	O
pyrexia	NN	pyrexia	pyrexia	pyrexia	Y	B-AdverseReaction
,	,	,	,	,	N	O
pallor	NN	pallor	pallor	pallor	Y	B-AdverseReaction
,	,	,	,	,	N	O
peripheral	JJ	peripheral	peripheral	peripher	N	B-AdverseReaction
coldness	NN	coldness	coldness	cold	Y	I-AdverseReaction
,	,	,	,	,	N	O
restlessness	NN	restlessness	restlessness	restless	Y	B-AdverseReaction
,	,	,	,	,	N	O
nervousness	NN	nervousness	nervousness	nervous	Y	B-AdverseReaction
,	,	,	,	,	N	O
headache	NN	headache	headache	headach	Y	B-AdverseReaction
,	,	,	,	,	N	O
back	RB	back	back	back	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
paresthesia	NN	paresthesia	paresthesia	paresthesia	Y	B-AdverseReaction
.	.	.	.	.	N	O

Some	DT	some	some	some	N	O
of	IN	of	of	of	N	O
these	DT	these	these	these	N	O
reactions	NNS	reactions	reaction	reaction	N	O
were	VBD	were	were	were	N	O
IgE	NNP	ige	ige	ige	Y	O
-	:	-	-	-	N	O
mediated	VBD	mediated	mediated	mediat	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
anaphylaxis	NNS	anaphylaxis	anaphylaxis	anaphylaxi	Y	O
or	CC	or	or	or	N	O
severe	JJ	severe	severe	sever	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	O
reactions	NNS	reactions	reaction	reaction	N	O
occur	VBP	occur	occur	occur	N	O
,	,	,	,	,	N	O
immediately	RB	immediately	immediately	immedi	N	O
discontinue	JJ	discontinue	discontinue	discontinu	N	O
administration	NN	administration	administration	administr	N	O
of	IN	of	of	of	N	O
alglucosidase	JJ	alglucosidase	alglucosidase	alglucosidas	N	O
alfa	NN	alfa	alfa	alfa	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
initiate	VB	initiate	initiate	initi	N	O
appropriate	JJ	appropriate	appropriate	appropri	N	O
medical	JJ	medical	medical	medic	N	O
treatment	NN	treatment	treatment	treatment	N	O
.	.	.	.	.	N	O

Severe	JJ	severe	severe	sever	N	O
reactions	NNS	reactions	reaction	reaction	N	O
are	VBP	are	are	are	N	O
generally	RB	generally	generally	gener	N	O
managed	VBN	managed	managed	manag	N	O
with	IN	with	with	with	N	O
infusion	NN	infusion	infusion	infus	Y	O
interruption	NN	interruption	interruption	interrupt	N	O
,	,	,	,	,	N	O
administration	NN	administration	administration	administr	N	O
of	IN	of	of	of	N	O
antihistamines	NNS	antihistamines	antihistamine	antihistamin	N	O
,	,	,	,	,	N	O
corticosteroids	NNS	corticosteroids	corticosteroid	corticosteroid	N	O
,	,	,	,	,	N	O
intravenous	JJ	intravenous	intravenous	intraven	N	O
fluids	NNS	fluids	fluid	fluid	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
oxygen	NN	oxygen	oxygen	oxygen	N	O
,	,	,	,	,	N	O
when	WRB	when	when	when	N	O
clinically	RB	clinically	clinically	clinic	N	O
indicated	VBN	indicated	indicated	indic	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
some	DT	some	some	some	N	O
cases	NNS	cases	case	case	N	O
of	IN	of	of	of	N	O
anaphylaxis	NN	anaphylaxis	anaphylaxis	anaphylaxi	Y	O
,	,	,	,	,	N	O
epinephrine	NN	epinephrine	epinephrine	epinephrin	Y	O
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
administered	VBN	administered	administered	administ	N	O
.	.	.	.	.	N	O

Appropriate	NNP	appropriate	appropriate	appropri	N	O
medical	JJ	medical	medical	medic	N	O
support	NN	support	support	support	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
cardiopulmonary	JJ	cardiopulmonary	cardiopulmonary	cardiopulmonari	N	O
resuscitation	NN	resuscitation	resuscitation	resuscit	Y	O
equipment	NN	equipment	equipment	equip	N	O
,	,	,	,	,	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
readily	RB	readily	readily	readili	N	O
available	JJ	available	available	avail	N	O
when	WRB	when	when	when	N	O
alglucosidase	NN	alglucosidase	alglucosidase	alglucosidas	N	O
alfa	NN	alfa	alfa	alfa	N	O
is	VBZ	is	is	is	N	O
administered	VBN	administered	administered	administ	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
risks	NNS	risks	risk	risk	N	O
and	CC	and	and	and	N	O
benefits	NNS	benefits	benefit	benefit	N	O
of	IN	of	of	of	N	O
re	NN	re	re	re	N	O
-	:	-	-	-	N	O
administering	VBG	administering	administering	administ	N	O
alglucosidase	JJ	alglucosidase	alglucosidase	alglucosidas	N	O
alfa	NN	alfa	alfa	alfa	N	O
following	VBG	following	following	follow	N	O
an	DT	an	an	an	N	O
anaphylactic	JJ	anaphylactic	anaphylactic	anaphylact	N	O
or	CC	or	or	or	N	O
hypersensitivity	JJ	hypersensitivity	hypersensitivity	hypersensit	Y	O
reaction	NN	reaction	reaction	reaction	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
considered	VBN	considered	considered	consid	N	O
.	.	.	.	.	N	O

Some	DT	some	some	some	N	O
patients	NNS	patients	patient	patient	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
rechallenged	VBN	rechallenged	rechallenged	rechalleng	N	O
and	CC	and	and	and	N	O
have	VBP	have	have	have	N	O
continued	VBN	continued	continued	continu	N	O
to	TO	to	to	to	N	O
receive	VB	receive	receive	receiv	N	O
alglucosidase	NN	alglucosidase	alglucosidase	alglucosidas	N	O
alfa	NN	alfa	alfa	alfa	N	O
under	IN	under	under	under	N	O
close	JJ	close	close	close	N	O
clinical	JJ	clinical	clinical	clinic	N	O
supervision	NN	supervision	supervision	supervis	N	O
.	.	.	.	.	N	O

Extreme	NNP	extreme	extreme	extrem	N	O
care	NN	care	care	care	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
exercised	VBN	exercised	exercised	exercis	N	O
,	,	,	,	,	N	O
with	IN	with	with	with	N	O
appropriate	JJ	appropriate	appropriate	appropri	N	O
resuscitation	NN	resuscitation	resuscitation	resuscit	Y	O
measures	NNS	measures	measure	measur	N	O
available	JJ	available	available	avail	N	O
,	,	,	,	,	N	O
if	IN	if	if	if	N	O
the	DT	the	the	the	N	O
decision	NN	decision	decision	decis	N	O
is	VBZ	is	is	is	N	O
made	VBN	made	made	made	N	O
to	TO	to	to	to	N	O
re	VB	re	re	re	N	O
-	:	-	-	-	N	O
administer	NN	administer	administer	administ	N	O
the	DT	the	the	the	N	O
product	NN	product	product	product	N	O
[	NNP	[	[	[	N	O
seeAdverse	NN	seeadverse	seeadverse	seeadvers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6.2	CD	6.2	6.2	6.2	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

5.2	CD	5.2	5.2	5.2	N	O
Immune	NNP	immune	immune	immun	N	O
-	:	-	-	-	N	O
Mediated	VBD	mediated	mediated	mediat	N	O
Reactions	NNS	reactions	reaction	reaction	N	O

Immune	NNP	immune	immune	immun	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
mediated	VBD	mediated	mediated	mediat	N	I-AdverseReaction
cutaneous	JJ	cutaneous	cutaneous	cutan	N	I-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
with	IN	with	with	with	N	O
alglucosidase	NN	alglucosidase	alglucosidase	alglucosidas	N	O
alfa	NN	alfa	alfa	alfa	N	O
including	VBG	including	including	includ	N	O
necrotizing	VBG	necrotizing	necrotizing	necrot	N	B-AdverseReaction
skin	JJ	skin	skin	skin	N	I-AdverseReaction
lesions	NNS	lesions	lesion	lesion	N	I-AdverseReaction
[	VBP	[	[	[	N	O
seeAdverse	JJ	seeadverse	seeadverse	seeadvers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6.3	CD	6.3	6.3	6.3	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Systemic	NNP	systemic	systemic	system	N	B-AdverseReaction
immune	JJ	immune	immune	immun	N	I-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
mediated	JJ	mediated	mediated	mediat	N	I-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
possible	JJ	possible	possible	possibl	N	B-Factor
type	NN	type	type	type	N	B-AdverseReaction
III	NNP	iii	iii	iii	N	I-AdverseReaction
immune	VBZ	immune	immune	immun	N	I-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
mediated	VBN	mediated	mediated	mediat	N	I-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
observed	VBN	observed	observed	observ	N	O
with	IN	with	with	with	N	O
alglucosidase	NN	alglucosidase	alglucosidase	alglucosidas	N	O
alfa	NN	alfa	alfa	alfa	N	O
.	.	.	.	.	N	O

These	DT	these	these	these	N	O
reactions	NNS	reactions	reaction	reaction	N	O
occurred	VBD	occurred	occurred	occur	N	O
several	JJ	several	several	sever	N	O
weeks	NNS	weeks	week	week	N	O
to	TO	to	to	to	N	O
3	CD	3	3	3	N	O
years	NNS	years	year	year	N	O
after	IN	after	after	after	N	O
initiation	NN	initiation	initiation	initi	N	O
of	IN	of	of	of	N	O
alglucosidase	NN	alglucosidase	alglucosidase	alglucosidas	N	O
alfa	NN	alfa	alfa	alfa	N	O
infusions	NNS	infusions	infusion	infus	N	O
.	.	.	.	.	N	O

Skin	NNP	skin	skin	skin	N	O
biopsy	NN	biopsy	biopsy	biopsi	Y	O
in	IN	in	in	in	N	O
one	CD	one	one	one	N	O
patient	NN	patient	patient	patient	N	O
demonstrated	VBD	demonstrated	demonstrated	demonstr	N	O
deposition	NN	deposition	deposition	deposit	N	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
anti	JJ	anti	anti	anti	N	I-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
rhGAA	NN	rhgaa	rhgaa	rhgaa	N	I-AdverseReaction
antibodies	NNS	antibodies	antibody	antibodi	N	I-AdverseReaction
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
lesion	NN	lesion	lesion	lesion	N	O
.	.	.	.	.	N	O

Another	DT	another	another	anoth	N	O
patient	NN	patient	patient	patient	N	O
developed	VBD	developed	developed	develop	N	O
severe	JJ	severe	severe	sever	N	B-Severity
inflammatory	NN	inflammatory	inflammatory	inflammatori	N	B-AdverseReaction
arthropathy	NN	arthropathy	arthropathy	arthropathi	Y	I-AdverseReaction
in	IN	in	in	in	N	O
association	NN	association	association	associ	N	O
with	IN	with	with	with	N	O
pyrexia	NN	pyrexia	pyrexia	pyrexia	Y	B-AdverseReaction
and	CC	and	and	and	N	O
elevated	VBD	elevated	elevated	elev	N	B-AdverseReaction
erythrocyte	JJ	erythrocyte	erythrocyte	erythrocyt	N	I-AdverseReaction
sedimentation	NN	sedimentation	sedimentation	sediment	N	I-AdverseReaction
rate	NN	rate	rate	rate	N	I-AdverseReaction
.	.	.	.	.	N	O

Nephrotic	JJ	nephrotic	nephrotic	nephrot	N	B-AdverseReaction
syndrome	NN	syndrome	syndrome	syndrom	N	I-AdverseReaction
secondary	JJ	secondary	secondary	secondari	N	O
to	TO	to	to	to	N	O
membranous	JJ	membranous	membranous	membran	N	B-AdverseReaction
glomerulonephritis	NN	glomerulonephritis	glomerulonephritis	glomerulonephr	Y	I-AdverseReaction
was	VBD	was	wa	wa	N	O
observed	VBN	observed	observed	observ	N	O
in	IN	in	in	in	N	O
some	DT	some	some	some	N	O
Pompe	NNP	pompe	pompe	pomp	N	O
disease	NN	disease	disease	diseas	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
alglucosidase	JJ	alglucosidase	alglucosidase	alglucosidas	N	O
alfa	NN	alfa	alfa	alfa	N	O
who	WP	who	who	who	N	O
had	VBD	had	had	had	N	O
persistently	RB	persistently	persistently	persist	N	O
positive	JJ	positive	positive	posit	N	B-AdverseReaction
anti	SYM	anti	anti	anti	N	I-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
rhGAA	NN	rhgaa	rhgaa	rhgaa	N	I-AdverseReaction
IgG	NNP	igg	igg	igg	Y	I-AdverseReaction
antibody	NN	antibody	antibody	antibodi	N	I-AdverseReaction
titers	NNS	titers	titer	titer	N	I-AdverseReaction
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
these	DT	these	these	these	N	O
patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
renal	JJ	renal	renal	renal	N	O
biopsy	NN	biopsy	biopsy	biopsi	Y	O
was	VBD	was	wa	wa	N	O
consistent	JJ	consistent	consistent	consist	N	O
with	IN	with	with	with	N	O
immune	JJ	immune	immune	immun	N	B-AdverseReaction
complex	JJ	complex	complex	complex	N	I-AdverseReaction
deposition	NN	deposition	deposition	deposit	N	I-AdverseReaction
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
improved	VBD	improved	improved	improv	N	O
following	VBG	following	following	follow	N	O
treatment	NN	treatment	treatment	treatment	N	O
interruption	NN	interruption	interruption	interrupt	N	O
.	.	.	.	.	N	O

Therefore	RB	therefore	therefore	therefor	N	O
,	,	,	,	,	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
alglucosidase	JJ	alglucosidase	alglucosidase	alglucosidas	N	O
alfa	NN	alfa	alfa	alfa	N	O
should	MD	should	should	should	N	O
undergo	VB	undergo	undergo	undergo	N	O
periodic	JJ	periodic	periodic	period	N	O
urinalysis	NN	urinalysis	urinalysis	urinalysi	Y	O
[	NNP	[	[	[	N	O
seeAdverse	NN	seeadverse	seeadverse	seeadvers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6.3	CD	6.3	6.3	6.3	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
monitored	VBN	monitored	monitored	monitor	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
development	NN	development	development	develop	N	O
of	IN	of	of	of	N	O
systemic	JJ	systemic	systemic	system	N	O
immune	JJ	immune	immune	immun	N	O
-	:	-	-	-	N	O
mediated	VBN	mediated	mediated	mediat	N	O
reactions	NNS	reactions	reaction	reaction	N	O
involving	VBG	involving	involving	involv	N	O
skin	NN	skin	skin	skin	N	O
and	CC	and	and	and	N	O
other	JJ	other	other	other	N	O
organs	NNS	organs	organ	organ	N	O
while	IN	while	while	while	N	O
receiving	VBG	receiving	receiving	receiv	N	O
alglucosidase	NN	alglucosidase	alglucosidase	alglucosidas	N	O
alfa	NN	alfa	alfa	alfa	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
immune	JJ	immune	immune	immun	N	O
-	:	-	-	-	N	O
mediated	VBN	mediated	mediated	mediat	N	O
reactions	NNS	reactions	reaction	reaction	N	O
occur	VBP	occur	occur	occur	N	O
,	,	,	,	,	N	O
consider	JJR	consider	consider	consid	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
administration	NN	administration	administration	administr	N	O
of	IN	of	of	of	N	O
alglucosidase	JJ	alglucosidase	alglucosidase	alglucosidas	N	O
alfa	NN	alfa	alfa	alfa	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
initiate	VB	initiate	initiate	initi	N	O
appropriate	JJ	appropriate	appropriate	appropri	N	O
medical	JJ	medical	medical	medic	N	O
treatment	NN	treatment	treatment	treatment	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
risks	NNS	risks	risk	risk	N	O
and	CC	and	and	and	N	O
benefits	NNS	benefits	benefit	benefit	N	O
of	IN	of	of	of	N	O
re	NN	re	re	re	N	O
-	:	-	-	-	N	O
administering	VBG	administering	administering	administ	N	O
alglucosidase	JJ	alglucosidase	alglucosidase	alglucosidas	N	O
alfa	NN	alfa	alfa	alfa	N	O
following	VBG	following	following	follow	N	O
an	DT	an	an	an	N	O
immune	JJ	immune	immune	immun	N	O
-	:	-	-	-	N	O
mediated	VBN	mediated	mediated	mediat	N	O
reaction	NN	reaction	reaction	reaction	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
considered	VBN	considered	considered	consid	N	O
.	.	.	.	.	N	O

Some	DT	some	some	some	N	O
patients	NNS	patients	patient	patient	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
able	JJ	able	able	abl	N	O
to	TO	to	to	to	N	O
be	VB	be	be	be	N	O
rechallenged	VBN	rechallenged	rechallenged	rechalleng	N	O
and	CC	and	and	and	N	O
have	VBP	have	have	have	N	O
continued	VBN	continued	continued	continu	N	O
to	TO	to	to	to	N	O
receive	VB	receive	receive	receiv	N	O
alglucosidase	NN	alglucosidase	alglucosidase	alglucosidas	N	O
alfa	NN	alfa	alfa	alfa	N	O
under	IN	under	under	under	N	O
close	JJ	close	close	close	N	O
clinical	JJ	clinical	clinical	clinic	N	O
supervision	NN	supervision	supervision	supervis	N	O
.	.	.	.	.	N	O

5.3	CD	5.3	5.3	5.3	N	O
Risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
Acute	NNP	acute	acute	acut	N	O
Cardiorespiratory	NNP	cardiorespiratory	cardiorespiratory	cardiorespiratori	N	O
Failure	NN	failure	failure	failur	N	O

Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
acute	JJ	acute	acute	acut	N	O
underlying	VBG	underlying	underlying	underli	N	O
respiratory	JJ	respiratory	respiratory	respiratori	N	O
illness	NN	illness	illness	ill	N	O
or	CC	or	or	or	N	O
compromised	VBN	compromised	compromised	compromis	N	O
cardiac	JJ	cardiac	cardiac	cardiac	N	O
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
respiratory	JJ	respiratory	respiratory	respiratori	N	O
function	NN	function	function	function	N	O
may	MD	may	may	may	N	B-Factor
be	VB	be	be	be	N	O
at	IN	at	at	at	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
serious	JJ	serious	serious	seriou	N	B-Severity
exacerbation	NN	exacerbation	exacerbation	exacerb	N	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
their	PRP$	their	their	their	N	O
cardiac	NN	cardiac	cardiac	cardiac	N	I-AdverseReaction
or	CC	or	or	or	N	O
respiratory	JJ	respiratory	respiratory	respiratori	N	I-AdverseReaction
compromise	NN	compromise	compromise	compromis	N	I-AdverseReaction
during	IN	during	during	dure	N	O
infusions	NNS	infusions	infusion	infus	N	O
.	.	.	.	.	N	O

Appropriate	NNP	appropriate	appropriate	appropri	N	O
medical	JJ	medical	medical	medic	N	O
support	NN	support	support	support	N	O
and	CC	and	and	and	N	O
monitoring	NN	monitoring	monitoring	monitor	N	O
measures	NNS	measures	measure	measur	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
readily	RB	readily	readily	readili	N	O
available	JJ	available	available	avail	N	O
during	IN	during	during	dure	N	O
alglucosidase	JJ	alglucosidase	alglucosidase	alglucosidas	N	O
alfa	JJ	alfa	alfa	alfa	N	O
infusion	NN	infusion	infusion	infus	Y	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
some	DT	some	some	some	N	O
patients	NNS	patients	patient	patient	N	O
may	MD	may	may	may	N	O
require	VB	require	require	requir	N	O
prolonged	JJ	prolonged	prolonged	prolong	N	O
observation	NN	observation	observation	observ	N	O
times	NNS	times	time	time	N	O
that	WDT	that	that	that	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
individualized	VBN	individualized	individualized	individu	N	O
based	VBN	based	based	base	N	O
on	IN	on	on	on	N	O
the	DT	the	the	the	N	O
needs	NNS	needs	need	need	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
patient	NN	patient	patient	patient	N	O
.	.	.	.	.	N	O

Acute	NNP	acute	acute	acut	N	B-AdverseReaction
cardiorespiratory	NN	cardiorespiratory	cardiorespiratory	cardiorespiratori	N	I-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
observed	VBN	observed	observed	observ	N	O
in	IN	in	in	in	N	O
infantile	JJ	infantile	infantile	infantil	N	O
-	:	-	-	-	N	O
onset	NN	onset	onset	onset	N	O
Pompe	NNP	pompe	pompe	pomp	N	O
disease	NN	disease	disease	diseas	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
underlying	JJ	underlying	underlying	underli	N	O
cardiac	JJ	cardiac	cardiac	cardiac	N	O
hypertrophy	NN	hypertrophy	hypertrophy	hypertrophi	Y	O
,	,	,	,	,	N	O
possibly	RB	possibly	possibly	possibl	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
fluid	NN	fluid	fluid	fluid	N	B-AdverseReaction
overload	NN	overload	overload	overload	N	I-AdverseReaction
with	IN	with	with	with	N	O
intravenous	JJ	intravenous	intravenous	intraven	N	O
administration	NN	administration	administration	administr	N	O
of	IN	of	of	of	N	O
alglucosidase	JJ	alglucosidase	alglucosidase	alglucosidas	N	O
alfa	NN	alfa	alfa	alfa	N	O
[	NNP	[	[	[	N	O
seeDosage	NN	seedosage	seedosage	seedosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.2	CD	2.2	2.2	2.2	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

5.4	CD	5.4	5.4	5.4	N	O
Risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
Cardiac	NNP	cardiac	cardiac	cardiac	N	O
Arrhythmia	NNP	arrhythmia	arrhythmia	arrhythmia	Y	O
and	CC	and	and	and	N	O
Sudden	NNP	sudden	sudden	sudden	N	O
Cardiac	NNP	cardiac	cardiac	cardiac	N	O
Death	NNP	death	death	death	Y	O
During	IN	during	during	dure	N	O
General	NNP	general	general	gener	N	O
Anesthesia	NNP	anesthesia	anesthesia	anesthesia	Y	O
for	IN	for	for	for	N	O
Central	NNP	central	central	central	N	O
Venous	NNP	venous	venous	venou	N	O
Catheter	NNP	catheter	catheter	cathet	N	O
Placement	NNP	placement	placement	placement	N	O

Administration	NN	administration	administration	administr	N	O
of	IN	of	of	of	N	O
general	JJ	general	general	gener	N	O
anesthesia	NN	anesthesia	anesthesia	anesthesia	Y	O
can	MD	can	can	can	N	O
be	VB	be	be	be	N	O
complicated	VBN	complicated	complicated	complic	N	O
by	IN	by	by	by	N	O
the	DT	the	the	the	N	O
presence	NN	presence	presence	presenc	N	O
of	IN	of	of	of	N	O
severe	JJ	severe	severe	sever	N	O
cardiac	NN	cardiac	cardiac	cardiac	N	O
and	CC	and	and	and	N	O
skeletal	NN	skeletal	skeletal	skelet	N	O
(	(	(	(	(	N	O
including	VBG	including	including	includ	N	O
respiratory	NN	respiratory	respiratory	respiratori	N	O
)	)	)	)	)	N	O
muscle	NN	muscle	muscle	muscl	N	O
weakness	NN	weakness	weakness	weak	Y	O
.	.	.	.	.	N	O

Therefore	RB	therefore	therefore	therefor	N	O
,	,	,	,	,	N	O
caution	NN	caution	caution	caution	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
used	VBN	used	used	use	N	O
when	WRB	when	when	when	N	O
administering	VBG	administering	administering	administ	N	O
general	JJ	general	general	gener	N	O
anesthesia	NN	anesthesia	anesthesia	anesthesia	Y	O
.	.	.	.	.	N	O

Ventricular	JJ	ventricular	ventricular	ventricular	N	B-AdverseReaction
arrhythmias	NN	arrhythmias	arrhythmia	arrhythmia	N	I-AdverseReaction
and	CC	and	and	and	N	O
bradycardia	NN	bradycardia	bradycardia	bradycardia	Y	B-AdverseReaction
,	,	,	,	,	N	O
resulting	VBG	resulting	resulting	result	N	O
in	IN	in	in	in	N	O
cardiac	JJ	cardiac	cardiac	cardiac	N	B-AdverseReaction
arrest	NN	arrest	arrest	arrest	N	I-AdverseReaction
or	CC	or	or	or	N	O
death	NN	death	death	death	Y	B-AdverseReaction
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
requiring	VBG	requiring	requiring	requir	N	O
cardiac	JJ	cardiac	cardiac	cardiac	N	O
resuscitation	NN	resuscitation	resuscitation	resuscit	Y	O
or	CC	or	or	or	N	O
defibrillation	NN	defibrillation	defibrillation	defibril	Y	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
observed	VBN	observed	observed	observ	N	O
in	IN	in	in	in	N	O
infantile	JJ	infantile	infantile	infantil	N	O
-	:	-	-	-	N	O
onset	NN	onset	onset	onset	N	O
Pompe	NNP	pompe	pompe	pomp	N	O
disease	NN	disease	disease	diseas	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
cardiac	JJ	cardiac	cardiac	cardiac	N	O
hypertrophy	NN	hypertrophy	hypertrophy	hypertrophi	Y	O
during	IN	during	during	dure	N	O
general	JJ	general	general	gener	N	O
anesthesia	NN	anesthesia	anesthesia	anesthesia	Y	O
for	IN	for	for	for	N	O
central	JJ	central	central	central	N	O
venous	JJ	venous	venous	venou	N	O
catheter	NN	catheter	catheter	cathet	N	O
placement	NN	placement	placement	placement	N	O
.	.	.	.	.	N	O

5.5	CD	5.5	5.5	5.5	N	O
Risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
Antibody	NNP	antibody	antibody	antibodi	N	O
Development	NNP	development	development	develop	N	O

As	IN	as	a	as	N	O
with	IN	with	with	with	N	O
all	DT	all	all	all	N	O
therapeutic	JJ	therapeutic	therapeutic	therapeut	N	O
proteins	NNS	proteins	protein	protein	N	O
,	,	,	,	,	N	O
there	EX	there	there	there	N	O
is	VBZ	is	is	is	N	O
potential	JJ	potential	potential	potenti	N	O
for	IN	for	for	for	N	O
immunogenicity	NN	immunogenicity	immunogenicity	immunogen	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
studies	NNS	studies	study	studi	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
majority	NN	majority	majority	major	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
developed	VBN	developed	developed	develop	N	O
IgG	NNP	igg	igg	igg	Y	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
to	TO	to	to	to	N	O
alglucosidase	VB	alglucosidase	alglucosidase	alglucosidas	N	O
alfa	NN	alfa	alfa	alfa	N	O
,	,	,	,	,	N	O
typically	RB	typically	typically	typic	N	O
within	IN	within	within	within	N	O
3	CD	3	3	3	N	O
months	NNS	months	month	month	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
.	.	.	.	.	N	O

There	EX	there	there	there	N	O
is	VBZ	is	is	is	N	O
evidence	NN	evidence	evidence	evid	N	O
to	TO	to	to	to	N	O
suggest	VB	suggest	suggest	suggest	N	O
that	IN	that	that	that	N	O
some	DT	some	some	some	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
develop	VBP	develop	develop	develop	N	O
high	JJ	high	high	high	N	O
and	CC	and	and	and	N	O
sustained	VBD	sustained	sustained	sustain	N	O
IgG	NNP	igg	igg	igg	Y	O
antibody	NN	antibody	antibody	antibodi	N	O
titers	NNS	titers	titer	titer	N	O
may	MD	may	may	may	N	B-Factor
experience	VB	experience	experience	experi	N	O
reduced	JJ	reduced	reduced	reduc	N	B-AdverseReaction
clinical	JJ	clinical	clinical	clinic	N	I-AdverseReaction
efficacy	NN	efficacy	efficacy	efficaci	N	I-AdverseReaction
to	TO	to	to	to	N	O
alglucosidase	VB	alglucosidase	alglucosidase	alglucosidas	N	O
alfa	JJ	alfa	alfa	alfa	N	O
treatment	NN	treatment	treatment	treatment	N	O
,	,	,	,	,	N	O
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
loss	NN	loss	loss	loss	N	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
motor	NN	motor	motor	motor	N	I-AdverseReaction
function	NN	function	function	function	N	I-AdverseReaction
,	,	,	,	,	N	O
ventilator	NN	ventilator	ventilator	ventil	N	O
dependence	NN	dependence	dependence	depend	Y	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
death	NN	death	death	death	Y	B-AdverseReaction
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
effect	NN	effect	effect	effect	N	O
of	IN	of	of	of	N	O
antibody	NN	antibody	antibody	antibodi	N	O
development	NN	development	development	develop	N	O
on	IN	on	on	on	N	O
the	DT	the	the	the	N	O
long	JJ	long	long	long	N	O
term	NN	term	term	term	N	O
efficacy	NN	efficacy	efficacy	efficaci	N	O
of	IN	of	of	of	N	O
alglucosidase	NN	alglucosidase	alglucosidase	alglucosidas	N	O
alfa	NN	alfa	alfa	alfa	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
fully	RB	fully	fully	fulli	N	O
understood	JJ	understood	understood	understood	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
monitored	VBN	monitored	monitored	monitor	N	O
for	IN	for	for	for	N	O
IgG	NNP	igg	igg	igg	Y	O
antibody	NN	antibody	antibody	antibodi	N	O
formation	NN	formation	formation	format	N	O
every	DT	every	every	everi	N	O
3	CD	3	3	3	N	O
months	NNS	months	month	month	N	O
for	IN	for	for	for	N	O
2	CD	2	2	2	N	O
years	NNS	years	year	year	N	O
and	CC	and	and	and	N	O
then	RB	then	then	then	N	O
annually	RB	annually	annually	annual	N	O
thereafter	RB	thereafter	thereafter	thereaft	N	O
.	.	.	.	.	N	O

Testing	VBG	testing	testing	test	N	O
for	IN	for	for	for	N	O
IgG	NNP	igg	igg	igg	Y	O
titers	NNS	titers	titer	titer	N	O
may	MD	may	may	may	N	O
also	RB	also	also	also	N	O
be	VB	be	be	be	N	O
considered	VBN	considered	considered	consid	N	O
if	IN	if	if	if	N	O
patients	NNS	patients	patient	patient	N	O
develop	VBP	develop	develop	develop	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	O
reactions	NNS	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
other	JJ	other	other	other	N	O
immune	JJ	immune	immune	immun	N	O
-	:	-	-	-	N	O
mediated	JJ	mediated	mediated	mediat	N	O
reactions	NNS	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
lose	VB	lose	lose	lose	N	O
clinical	JJ	clinical	clinical	clinic	N	O
response	NN	response	response	respons	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
experience	VBP	experience	experience	experi	N	O
reduced	VBN	reduced	reduced	reduc	N	O
clinical	JJ	clinical	clinical	clinic	N	O
response	NN	response	response	respons	N	O
may	MD	may	may	may	N	O
also	RB	also	also	also	N	O
be	VB	be	be	be	N	O
tested	VBN	tested	tested	test	N	O
for	IN	for	for	for	N	O
inhibitory	JJ	inhibitory	inhibitory	inhibitori	N	O
antibody	NN	antibody	antibody	antibodi	N	O
activity	NN	activity	activity	activ	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
experience	VBP	experience	experience	experi	N	O
anaphylactic	JJ	anaphylactic	anaphylactic	anaphylact	N	O
or	CC	or	or	or	N	O
hypersensitivity	JJ	hypersensitivity	hypersensitivity	hypersensit	Y	O
reactions	NNS	reactions	reaction	reaction	N	O
may	MD	may	may	may	N	O
also	RB	also	also	also	N	O
be	VB	be	be	be	N	O
tested	VBN	tested	tested	test	N	O
for	IN	for	for	for	N	O
IgE	NNP	ige	ige	ige	Y	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
to	TO	to	to	to	N	O
alglucosidase	VB	alglucosidase	alglucosidase	alglucosidas	N	O
alfa	NN	alfa	alfa	alfa	N	O
and	CC	and	and	and	N	O
other	JJ	other	other	other	N	O
mediators	NNS	mediators	mediator	mediat	N	O
of	IN	of	of	of	N	O
anaphylaxis	JJ	anaphylaxis	anaphylaxis	anaphylaxi	Y	O
[	NNP	[	[	[	N	O
seeAdverse	NN	seeadverse	seeadverse	seeadvers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6.2	CD	6.2	6.2	6.2	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

There	EX	there	there	there	N	O
are	VBP	are	are	are	N	O
currently	RB	currently	currently	current	N	O
no	RB	no	no	no	N	O
marketed	JJ	marketed	marketed	market	N	O
tests	NNS	tests	test	test	N	O
for	IN	for	for	for	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
against	IN	against	against	against	N	O
alglucosidase	NN	alglucosidase	alglucosidase	alglucosidas	N	O
alfa	NN	alfa	alfa	alfa	N	O
;	:	;	;	;	N	O
however	RB	however	however	howev	N	O
,	,	,	,	,	N	O
a	DT	a	a	a	N	O
testing	JJ	testing	testing	test	N	O
service	NN	service	service	servic	N	O
is	VBZ	is	is	is	N	O
provided	VBN	provided	provided	provid	N	O
by	IN	by	by	by	N	O
Genzyme	NNP	genzyme	genzyme	genzym	N	O
.	.	.	.	.	N	O

Contact	VB	contact	contact	contact	N	O
your	PRP$	your	your	your	N	O
local	JJ	local	local	local	N	O
Genzyme	NNP	genzyme	genzyme	genzym	N	O
representative	NN	representative	representative	repres	N	O
or	CC	or	or	or	N	O
Genzyme	NNP	genzyme	genzyme	genzym	N	O
Corporation	NNP	corporation	corporation	corpor	N	O
at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
800	CD	800	800	800	N	O
-	:	-	-	-	N	O
745	CD	745	745	745	N	O
-	:	-	-	-	N	O
4447	CD	4447	4447	4447	N	O
for	IN	for	for	for	N	O
information	NN	information	information	inform	N	O
on	IN	on	on	on	N	O
testing	VBG	testing	testing	test	N	O
and	CC	and	and	and	N	O
to	TO	to	to	to	N	O
obtain	VB	obtain	obtain	obtain	N	O
a	DT	a	a	a	N	O
sample	JJ	sample	sample	sampl	N	O
collection	NN	collection	collection	collect	N	O
box	NN	box	box	box	N	O
.	.	.	.	.	N	O

